Identification of novel small molecule inhibitors of proteins required for genomic maintenance and stability by Shuck, Sarah C.
 
 
 
 
IDENTIFICATION OF NOVEL SMALL MOLECULE INHIBITORS OF 
PROTEINS REQUIRED FOR GENOMIC MAINTENANCE AND 
STABILITY 
 
 
 
 
 
Sarah C. Shuck 
 
 
 
 
 
 
 
Submitted to the faculty of the University Graduate School 
in partial fulfillment of the requirements  
for the degree 
Doctor of Philosophy 
in the Department of Biochemistry and Molecular Biology,  
Indiana University 
 
June 2010 
  
ii 
 
Accepted by the Faculty of Indiana University, in partial 
fulfillment of the requirements for the degree of Doctor of Philosophy. 
 
 
 
 
 
 
John J. Turchi, Ph.D., Chair 
 
 
    Mark R. Kelley, Ph.D. 
Doctoral Committee 
 
 Thomas D. Hurley, Ph.D. 
April 16, 2010 
                 
Frank A. Witzmann, Ph.D. 
  
iii 
 
ACKNOWLEDGEMENTS 
Foremost I would like to thank my thesis advisor Dr. John Turchi for his 
assistance, support and advice.  He has gone above and beyond to provide me with 
wonderful advice, both professionally and scientifically.  He has also been an amazing 
person to work for and with throughout my time here.  I would also like to thank the 
other members of my committee, Dr. Mark Kelley, Dr. Tom Hurley and Dr. Frank 
Witzmann for their advice and help in earning my Ph.D.  The members of the Turchi lab, 
especially Katie Pawelczak, have been a tremendous source of help, advice and 
friendship over the years.  I would also like to specifically thank Brooke Andrews, Emily 
Short, John Montgomery and Victor Anciano for working closely with me on my project 
and really helping to keep it moving forward.  I would also like to thank my family for 
supporting me throughout all of my higher education, it has been a very long road!  My 
dad has given me so much wonderful advice about both work and life and his words will 
always stick with me.  My mother has been a great friend and ear over the years.  I would 
especially like to thank my brother and sister, Josh and Jodi, for all of their love and 
support throughout the years.   
 
  
iv 
 
ABSTRACT 
Sarah C. Shuck 
 Targeting uncontrolled cell proliferation and resistance to DNA damaging 
chemotherapeutics using small molecule inhibitors of proteins involved in these pathways 
has significant potential in cancer treatment.  Several proteins involved in genomic 
maintenance and stability have been implicated both in the development of cancer and 
the response to chemotherapeutic treatment.  Replication Protein A, RPA, the eukaryotic 
single-strand DNA binding protein, is essential for genomic maintenance and stability via 
roles in both DNA replication and repair.  Xeroderma Pigmentosum Group A, XPA, is 
required for nucleotide excision repair, the main pathway cells employ to repair bulky 
DNA adducts.  Both of these proteins have been implicated in tumor progression and 
chemotherapeutic response.  We have identified a novel small molecule that inhibits the 
in vitro and cellular ssDNA binding activity of RPA, prevents cell cycle progression, 
induces cytotoxicity and increases the efficacy of chemotherapeutic DNA damaging 
agents.  These results provide new insight into the mechanism of RPA-ssDNA 
interactions in chromosome maintenance and stability.  We have also identified small 
molecules that prevent the XPA-DNA interaction, which are being investigated for 
cellular and tumor activity.  These results demonstrate the first molecularly targeted 
eukaryotic DNA binding inhibitors and reveal the utility of targeting a protein-DNA 
interaction as a therapeutic strategy for cancer treatment.  
Identification of novel small molecule inhibitors of proteins required for genomic 
maintenance and stability 
John J. Turchi, Ph.D. 
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1. Genomic Stability and Maintenance in Cancer 
 Cells rely on highly coordinated pathways and checkpoints to execute proper 
DNA replication and cell division (1).  Dysregulation of these pathways from protein 
aberrations results in uncontrolled cell proliferation, which is a hallmark of the 
development of cancer (2).  Many current chemotherapeutic agents exert their cytotoxic 
effect by inhibiting or counteracting the activity of mutated proteins that are no longer 
able to properly regulate cell growth.  Cancer cells can acquire resistance to these drugs, 
which reduces the drug’s effectiveness and presents a major hindrance regarding the 
treatment of cancer patients.  Therefore, targeting essential regulatory proteins that are 
required for both normal cell proliferation and the response to chemotherapeutic 
treatment has the potential for widespread impact and utility for cancer therapy.   
 In order for cells to proliferate, they must progress through the cell cycle and 
efficiently replicate their DNA.  Replication Protein A (RPA) is a eukaryotic single-
strand DNA (ssDNA) binding protein that is involved in several DNA metabolic 
pathways including DNA replication (3).  RPA is also essential in numerous DNA repair 
pathways including the nucleotide excision repair (NER) pathway, which is the main 
pathway cells employ to repair bulky DNA adducts (3).  In addition to RPA, several other 
proteins are required for NER including Xeroderma Pigmentosum Group A (XPA), 
which has been implicated both in the development of cancer as well as in the response to 
chemotherapeutic treatment (4).  Small molecule inhibitors of RPA and XPA have the 
potential for development into clinically significant treatments for a wide variety of 
malignancies with both single agent activity, in the case of RPA inhibition, and in 
combination therapy with chemotherapeutic agents that target genomic stability.  The 
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small molecule inhibitors we have identified represent the first molecularly targeted 
eukaryotic DNA binding inhibitors and reveal the utility of targeting a protein-DNA 
interaction as a therapeutic strategy for cancer treatment. 
1.1.  Cancer Development 
 Cancer currently accounts for a quarter of all deaths in the United States and the 
rate of cancer deaths from 1991 to 2006 has decreased by only 16%, justifying the need 
for more effective cancer therapies (US Mortality Data 2006, National Center for Health 
Statistics, Centers for Disease Control and Prevention, 2009).  Currently, lung cancer is 
the leading cause of cancer-related mortality, causing 30% of all cancer deaths in males 
and 26% in females (American Cancer Society, 2009).  Standard therapy for lung cancer 
includes the use of chemotherapeutic agents combined with radiation therapy and surgery 
(5, 6).  The development of lung cancer and its response to treatment is multi-factorial.  
Although the cellular genotype of each cancer cell is different, most cancers are believed 
to develop following the alteration of six essential regulatory mechanisms known as the 
hallmarks of cancer.  These include an insensitivity to anti-growth signals, sustained 
angiogenesis, limitless replicative potential, tissue invasion and metastasis, evading 
apoptosis and self sufficiently in growth signals (2).   
 The dysregulation of cellular processes that contribute to the hallmarks of cancer 
can be attributed to changes at the molecular level.  A series of acquired changes in the 
genomic sequence leading to improper protein expression and/or activity has the potential 
to lead to uncontrolled cell proliferation.  Previous hypotheses have suggested a “two-hit” 
mechanism for tumor development in which a mutant allele is inherited from one parent 
and another later mutation is acquired throughout a person’s lifetime (7).  These 
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mutations lead to altered protein expression and/or activity.  Cellular pathways are in 
place to prevent mutations in the DNA sequence; however, DNA mutations do occur.  
This can lead to protein miscoding and loss of normal protein function or expression, 
which if the altered protein participates in the pathways identified by the six hallmarks of 
cancer, can lead to cancerous cell growth.  
1.2.  DNA Replication and Repair to Maintain Genomic Integrity 
 During normal cell division, cells go through four distinct stages of the cell cycle 
including G1, S, G2, and mitosis.  These processes are tightly regulated by a number of 
checkpoints to ensure that each step is completed properly before the cell progresses on 
to the next.  In order to propagate, cells must replicate their entire genome during S-phase 
so that during mitosis the daughter cells contain the entire unaltered genomic sequence, 
indicating the high fidelity that is required during DNA replication.  Misincorporation of 
a base may or may not lead to a difference in the final protein amino acid sequence; 
however, if the altered base leads to a change in the amino acid, the structure, function 
and/or expression of the protein may be altered.  If the expressed protein functions 
differently than the wild type protein, the overall cellular effect of the protein may 
become altered as well.  This illustrates the importance of maintaining the genomic 
sequence in order to sustain normal cellular function. 
 When DNA is damaged or altered, the changes do not necessarily have an impact 
on the overall cell population.  Phenotypic problems arise when DNA obtains a heritable 
change in the sequence, which is referred to as a mutation.  These differences are then 
propagated on to daughter cells and eventually a large cell population exists containing 
the mutation.  Mutations in the DNA contribute to cancer development, however, 
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changes are also evidenced in genetically transmitted diseases such as cystic fibrosis, 
phenylketonuria and Xeroderma Pigmentosum (XP) (8, 9, 9).  These diseases are 
characterized by hereditary genetic mutations in the DNA that result in either individual 
protein mutations or a combination of mutations that result in strong phenotypic 
characteristics.  These diseases are characterized by changes in protein function that 
result from genomic mutations.  Further understanding of how DNA mutagenesis results 
in the development of diseases can give insight into the development and progression of 
cancer as well as how and why cancers respond to current chemotherapeutic treatments. 
 In addition to mutations in DNA that can occur as a product of faulty replication, 
other agents can induce damage to the DNA that can result in improper base pairing, gaps 
formed in the DNA, and bulky lesions that disrupt the Watson and Crick double-strand 
DNA (dsDNA) helix (10).  One example of a chemical alteration in DNA is the 
formation of 8-oxoguanine (8-oxoG), which is produced as a result of a chemical reaction 
between guanine and a reactive oxygen species (ROS) (10).  Typically, guanine (G) bases 
pairs with cytosines (C), however, 8-oxoG mispairs with adenine, leading to a change in 
the DNA sequence (10).  The formation of 8-oxoG has the potential to be particularly 
mutagenic because cells are constantly exposed to ROS that can induce DNA damage 
and 8-oxoG is not always readily recognized by repair machinery (10).  The mispairing 
between G and A has the potential to cause deleterious effects to the cell if the change in 
sequence leads to a mutant protein.   
 Mutations that are induced in somatic cells as opposed to germ cells do not 
necessarily lead to genetic changes that are passed onto offspring, but rather are heritable 
from one cell to another in the same organism.  Therefore, mutations that accumulate in 
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somatic cells can lead to the development of diseases such as cancer and diabetes and 
also contribute to aging.  In order to counteract the DNA damage induced by exogenous 
and endogenous agents, cellular regulatory systems are in place to recognize and repair 
DNA damage. 
1.3.  DNA Replication 
 In order to maintain the integrity of the genomic sequence, S-phase DNA 
replication is tightly regulated in order to ensure that replication occurs in a timely 
manner, but also to make certain that the genome is accurately replicated (11).  For this to 
occur, the cell must coordinate the formation of multi-protein complexes at several 
origins of replication throughout the genome (12).  The regulation of protein complex 
formation is initiated during the G1-phase of the cell cycle by the formation of the pre-
replication complex (pre-RC), which assembles at origins of replication (12).  The 
formation of pre-RCs occurs in a two-step mechanism which involves the binding of 2 
helicase complexes (Mcm2-7) in opposite orientations by the activity of Cdc6 and Cdt1 
in an ATP-dependent mechanism (Figure 1) (11).  The loading of two Mcm2-7 
complexes in opposite orientations at replication origins allows for bi-directional DNA 
replication that is characteristic of eukaryotic DNA replication (11).  Once the initial pre-
RC has been formed, the cell is licensed to proceed into S-phase, which is allowed by the 
inactivation of the anaphase promoting complex (APC) at the G1/S transition (Figure 1) 
(13, 14).  Inactivation of the APC allows for the activation of kinases, including S-CDK  
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Figure 1.  DNA replication.  Formation of the pre-replication complex occurs during the 
G1 phase of the cell cycle and involves loading of two Mcm2-7 helicase complexes in 
opposite orientations from the origin of replication to allow for bi-directional DNA 
replication.  This activity is coordinated by Cdt1 and cdc6.  During the transition from G1 
to early S, Mcm10 is recruited to the sites of replication.  This occurs by inactivation of 
APC and activation of S-CDK and cdc7/Dbf4.  Following this formation, the DNA 
around the origin of replication is unwound and polymerase alpha is recruited to begin 
replicating the DNA and RPA is recruited to bind to unannealed ssDNA to prevent 
reannealing.  From this point, DNA replication proceeds to replicate the entire genome 
with the activity of other proteins not pictured including topoisomerases. 
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and Cdc7/Dbf4, that are important for permitting the cell to progress through the cell 
cycle (13).  These proteins along with the activity of several others work to form the pre-
initiation complex (pre-IC), which is in part responsible for ensuring that individual 
replication forks fire only once during S-phase (11).  Cyclin-dependent kinases (CDKs) 
directly prevent the formation of the pre-RC, and therefore the formation of these 
complexes can only occur during G1, when the activity of CDKs is low (11).  Mcm2-7 
helicases that are bound at the origin of replication work to unwind dsDNA and lead to 
the formation of ssDNA, which is bound by RPA (Figure 1) (15).  Upon DNA 
unwinding, DNA polymerase α is recruited to prime the template and to begin replicating 
the DNA (16).  As the DNA replication machinery progresses along the length of DNA, 
regions downstream of the replication machinery that have not yet been replicated 
become positively supercoiled in relation to the DNA that has been unwound (17).  In 
order to relieve the torsional stress induced upon the DNA, topoisomerase proteins are 
needed to produce breaks in the DNA backbone and then rejoin the DNA strand, 
allowing DNA replication to proceed (17, 18).   
The overall mechanism of DNA replication has been conserved throughout all 
eukaryotes, however the intricacies of each pathway including the proteins involved and 
how they are regulated, can vary between organisms (19).  The number of steps and 
checkpoints required to initiate DNA replication coupled with the energy the cell expends 
to carefully proofread the DNA indicate the inherent importance of maintaining genomic 
integrity.  If DNA damage has been induced and is not repaired or if proteins involved in 
DNA replication have been dysregulated, the cell does not proceed further until the 
damage has been repaired or the proteins are correctly regulated (20).  This response 
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involves the coordination and overlap between several different pathways in order to 
ultimately result with either accurate repair of DNA or the induction of apoptosis (20).   
RPA is required for preventing the reannealing of dsDNA unwound by helicases 
following initiation of replication and it has also been shown to interact with and 
modulate the activity of several proteins involved in DNA metabolism including DNA 
polymerase α (21).  RPA is important for both the initiation of replication when the 
Mcm2-7 helicases unwind dsDNA, as well as during elongation, when dsDNA is being 
unwound ahead of the replication fork.  The role of RPA is thought to not only be in 
preventing DNA strand reannealing, but also to regulate proteins involved in DNA 
metabolism.   
1.4.  DNA Repair Pathways 
 In addition to the role of proteins involved in DNA replication for maintaining 
genomic integrity, several pathways within the cell regulate the removal and repair of 
induced DNA damage.  While some signaling crosstalk occurs between these pathways, 
the mechanism of damage recognition distinguishes the pathways from each other and 
allows for the removal of almost every type of DNA lesion.  The coordination of multiple 
proteins within each pathway allows for efficient repair of DNA to reduce the number of 
potential mutations and to prevent the development of disease. 
1.4.1.  Base Excision Repair 
 Base excision repair (BER) is the main pathway cells use to repair non-bulky 
DNA base damage induced by endogenous and exogenous sources.  It is activated in 
response to damaged base residues and nucleotides as well as in response to abasic sites 
(22, 23).  The main source of endogenous chemical changes in the DNA result from 
9 
 
reactive oxygen and nitrogen species that are produced from normal cellular metabolism, 
however BER also repairs damage from environmental/therapeutic alkylating agents, 
such as temozolomide (TMZ) and methylating agents including methyl methanesulfonate 
(MMS) (10, 23).   
 BER is an important pathway for repairing DNA damage that is constantly being 
induced, for example 8-oxo-G, and ensuring that the genomic sequence remains unaltered 
(24).  The recognition of nonbulky DNA damage by the BER pathway is initiated by 
damage-specific DNA glycosylases that create abasic or apurinic/apyrimidinic (AP) sites, 
which can then be recognized by AP endonuclease 1 (APE 1) (22).  APE 1 cleaves the 
phosphodiester backbone leaving a free 3′-hydroxyl group and a 5′-deoxyribose 
phosphate surrounding the nucleotide gap (22).  Following this step, two subpathways, 
long patch BER and short patch BER, are available to further process the DNA resulting 
in polymerase addition of the correct base and ligation of the DNA strand (24).  Although 
there are two distinct sub-pathways of BER, there is overlap between the two with both 
involving Poly (ADP-ribose) polymerase (PARP), which acts enzymatically to 
poly(ADP-ribos)ylate other proteins and to autoribosylate, which results in its release 
from DNA, allowing DNA repair to continue (23).  PARP is currently being targeted for 
inhibition using chemical agents, the majority of which compete with NAD+ to bind to 
the active site of PARP (22, 25).  PARP -/- mouse fibroblasts have been shown to have 
increased sensitivity to methylating agents such as MMS, indicating the potential for 
combination therapy with alkylating/methylating agents in conjunction with inhibitors of 
the BER pathway (23). 
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1.4.2.  Mismatch Repair 
 Chemical modification of bases is one manner in which DNA damage is induced, 
however, mispairing of bases during DNA replication can also compromise genomic 
integrity.  DNA polymerases ensure correct base insertion during DNA replication by 
employing mechanisms including base discrimination during initial substrate binding and 
3'-5'exonuclease (exo) proofreading activity, however these mechanisms are not infallible 
and mistakes can be made (26).  Mismatch repair (MMR) is the pathway used to repair 
incorrect base insertions during DNA replication to prevent errors from becoming 
permanent in dividing cells (27).  Proteins involved in both E. coli and human MMR 
have been described, however a complete description of all of the proteins involved and 
their function has not been thoroughly described for humans (27).  Functional homology 
between proteins found in E. coli and humans has been described, allowing for 
identification of factors likely missing from human MMR (27).  E. coli MutS (human 
hMutSα (MSH2-MSH6) and hMutSβ (MSH2-MSH3)) is a homodimer that is referred to 
as the “mismatch recognition” protein and is responsible for recognizing base-base 
mismatches and small insertion and deletion mispairs.  MutS contains intrinsic ATPase 
activity that is required for MMR (27).  MutL (human MutLα (MLH1-PMS2), hMutLβ 
(MLH1-PMS2) and hMutLγ (MLH1-MLH3)) functions as a homodimer with intrinsic 
ATPase activity that physically interacts with MutS to enhance recognition (27).  MutL 
has been shown to interact with several proteins involved in MMR as well as DNA 
replication, including MutS and DNA polymerase III, respectively, indicating a role for 
MutL as a factor to increase functional MMR complex assembly and suggesting a mode 
of linking MMR to DNA replication (27).  Hemi-methylated DNA serves as a marker for 
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discriminating between parental and daughter DNA strands in E. coli in which the 
daughter strand is unmethylated and the parental strand contains methylation at the N6 
position of adenine (27).  This differential methylation serves as the signal for E. coli 
MutH, which does not have a known human homolog, to recognize the parental DNA 
strand, which presumably contains the correct DNA sequence (27).   
The combined activities of proteins involved in MMR with the actions of 
additional helicases and polymerase III result in removal of the base-base mismatch and 
resynthesis of the correct DNA sequence from the parental template (27).  Using in vitro 
reconstitution experiments, RPA has been shown to have a role in human MMR and has 
been suggested to bind and protect ssDNA during this repair pathway (28).  The 
importance of this pathway in maintaining genomic stability is evidenced by hereditary 
nonpolyposis colon cancer (HNPCC) in which patients have mutations in the gene 
encoding the human homologs of MutS and MutL (29).  hMSH2 is within the 
chromosome locus to which HNPCC genetic defects have been mapped and was the first 
mismatch repair protein to be identified to be linked to HNPCC (30, 31).  Since that time, 
additional mutations in proteins in the MMR pathway including hMLH1 and PMS2, have 
been identified and correlated with HNPCC (32).  Mutations in these proteins lead to 
deficient MMR, resulting in microsatellite instability and incorrect insertion of bases 
(27).  Microsatellite instability is characterized by nucleotide insertions and deletions that 
result in miscoded proteins that can lead to neoplastic growth (33).  Regions of genomic 
instability typically occur at particular sites known as “hotspots” and microsatellite 
polymorphisms are used as a both a prognostic and diagnostic tool in disease states  (27, 
33).  
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 MMR-deficient cells have been shown to be resistant to certain chemotherapeutic 
treatments such as TMZ and cisplatin, which presents opportunities for using MMR 
status both as a predictive marker for cancer development and as a means of predicting 
tumor response to chemotherapy (27).  Another interesting aspect of MMR in response to 
chemotherapy is that many cancers acquire mutations in MMR genes following 
treatment, causing cytotoxicity in non-cancerous, rapidly dividing MMR-proficient cells 
(27).  In addition, cancer cells that are MMR-proficient may be killed by chemotherapy, 
however, the treatment may induce mutations in MMR genes in other cells, leading to the 
development of secondary cancers (27).  These characteristics of MMR-proficient and 
deficient cells have important implications in cancer therapy both in the treatment and 
screening of cancer patients, and more needs to be elucidated about the human MMR 
pathway to allow it to be further exploited for therapeutic benefit (27). 
1.4.3.  Nucleotide Excision Repair 
 As evidenced in the case of MMR, cellular ability to repair DNA damage is 
required to maintain genomic integrity.  The nucleotide excision repair (NER) pathway 
removes bulky DNA adducts caused by exogenous and endogenous sources including 
UV irradiation and chemical mutagens (4).  The repair of bulky DNA damage is initiated 
by a damage recognition step and assembly of a pre-incision complex, followed by 
excision of the damaged strand and gap-filling DNA synthesis (4).  There are two 
subpathways of NER, global genomic repair (GG-NER), which recognizes DNA damage 
by proteins in the NER pathway and repairs DNA damage found throughout the genome, 
and transcription-coupled repair (TC-NER), which is activated by stalling of RNA 
polymerase II to repair damage on actively transcribed genes (4).  Once initial  
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Figure 2.  Eukaryotic Nucleotide Excision Repair.  Nuleotide excision repair is iniated 
by either pauing of RNA pol II during transcription (TC-NER) or by recognition of 
damage by XPC/RAD23B (GG-NER).  From this point the pathways converge and 
additional proteins including RPA, XPA and TFIIH are recruited to the site of damage.  
As these proteins are recruited, XPC/RAD23B becomes dissociated from the DNA (in 
GG-NER) and the endonucleases XPF and XPF are recruited to make 5′ and 3′ incisions 
around the site of damage as indicated by the black arrows.  Following incision, the 
damaged piece of DNA is removed and RPA remains bound to the single-strand region of 
DNA.   Po lymerase δ or ε are recru ited  to  the DNA along with  PCNA and  the excised 
region of DNA is filled in.  Ligase I is then recruited to seal the nick in the DNA resulting 
in repaired, double-strand DNA. 
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Table 1.  NER factors 
XPA      p36      damage verification  phosphorylation 
Factor subunits/associations         Activity           PTM      
XPB     TFIIH      helicase 
XPC     RAD23B     damage recognition  ubiquitylation 
      centrin-2       sumoylation 
    
 
XPD     TFIIH      helicase 
XPE     DDB1, DDB2     damage recognition  ubiquitylation 
          E3-ligase 
 
XPF     ERCC1     incision 
XPG         incision 
 
 
RPA     p70/p34/p14     damage recognition  phosphorylation 
          resynthesis 
 
Pol epsilon/DNA ligase I     Gap-filling/ligation 
Pol delta/ XRCC1-DNA ligase IIIα    Gap-filling/ligation 
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recognition has occurred, the pathways converge for the excision and gap filling steps 
(Figure 2).  
The six core factors involved in the damage recognition and dual incision steps of 
GG-NER are the XPC-RAD23B complex, transcription factor IIH (TFIIH), XPA, RPA, 
XPG, and XPF-ERCC1 (Table 1) (34).  Following damage recognition, the 9 subunit 
transcription factor IIH (TFIIH) complex is recruited to the site of damage.  TFIIH has 
helicase activity (via XPB and XPD) that unwinds DNA around the site of damage to 
allow further processing, but it also interactions with other proteins in the pathway, 
including XPA.  After TFIIH is recruited and the pre-incision complex with XPA and 
RPA has formed, XPG and XPF-ERCC1 are recruited to the site of damage to make the 
3′ and 5′ incisions, respectively, around the lesion to form an excision product of 27-29 
nucleotides (35).  Upon excision of the damaged DNA, DNA polymerase ε or δ, PCNA 
and RFC are used to fill in the gap and DNA ligase is used to seal the nick (Figure 2).    
Xeroderma Pigmentosum, XP, is an autosomal recessive disease with 7 
complementation groups and a single variant that is categorized by extreme sensitivity to 
sunlight and a predisposition to cancer, predominantly skin cancer (9).  The clinical 
manifestations of this disease result from decreased DNA repair capacity resulting from 
mutations in proteins required in the NER pathway.  In 1968, a direct link was found 
between DNA repair and carcinogenesis following the observation that cells derived from 
XP patients were unable to repair ultraviolet (UV) induced DNA damage, leading to a 
predisposition to cancer (36).  The analysis of XP allowed the delineation of the NER 
pathway with each complementation group, XPA through XPG, corresponding to an 
essential protein in the pathway (Table 1).  Over the past decade, there have been major 
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advancements in the understanding of XP and its relationship to DNA repair, further 
clarifying numerous aspects of the NER pathway.  This work has allowed for further 
understanding of how variations in NER proteins, including expression level, mutations 
and single nucleotide polymorphisms (SNPs), can increase an individual’s susceptibility 
to cancer as well as predict the response to chemotherapeutic treatments. 
Proteins important for NER have been implicated in the development of cancer, 
such as in the case of XP, but they have also been linked to chemotherapeutic response. 
Testicular cancer presents a 90% cure rate with combination cisplatin treatment (37).  
The dramatic response of testicular cancer to cisplatin has been thought to be correlated 
to cellular DNA repair capacity.  Previous work has shown a correlation between NER 
protein levels (XPA, ERCC1, and XPF) and the ability of cells to repair cisplatin lesions, 
for example, testis tumor cell lines have decreased levels of NER proteins and decreased 
cisplatin repair capacity (38, 39).  A decrease in cisplatin repair can lead to persistent 
DNA lesions which, if left unrepaired, can increase cytotoxicity, the mechanism thought 
to contribute to the sensitivity of testicular cancer to cisplatin treatment.  This presents 
the possibility of inhibiting DNA repair capacity to increase cellular sensitivity to DNA 
damaging agents that are repaired by the NER pathway.  Small molecule inhibitors of 
proteins required for NER, including XPA and RPA, would be predicted to increase 
cellular sensitivity to cisplatin, in much the same way that decreased levels of these 
proteins result in increased cellular sensitivity to cisplatin treatment. 
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1.4.4.  Double-Strand DNA Break Repair 
 Double-strand DNA breaks (DSBs) occur when endogenous and/or exogenous 
agents induce a break in the DNA backbone (40).  The breaks induced in the 
phosphodiester backbone of the DNA can result from ROS produced from either cellular 
metabolism or from ionizing radiation (IR) (41).  Following a dsDNA break, 
chromosomes become unstable and fragments can move and insert themselves 
indiscriminately or can be separated unequally between progeny cells (40).  These types 
of lesions can be repaired, however if cellular mechanisms do not accurately respond to 
these lesions, deletion or insertion of chromosome fragments can activate oncogenes 
and/or inactivate tumor suppressors, leading to carcinogenesis (40).  Several mechanisms 
are in place to lead to repair of DNA strand breaks that are activated by cell cycle 
checkpoints that arrest cell cycle progression in order to allow repair of the DSB (40). 
 Two distinctive pathways have been identified in mammalian cells that are 
responsible for repairing DSBs, homology directed repair (HDR) and non-homologous 
end joining (NHEJ) (40).  NHEJ is also the cellular mechanism for introducing diversity 
into immune cells during V(D)J recombination (40).  HDR and NHEJ vary in the proteins 
involved and in the accuracy of repair.  HDR is very accurate because a sister chromatid 
serves as the template for repair of the parental strand while NHEJ involves the joining of 
non-compatible ends, which can lead to mutations in the DNA sequence in addition to 
loss of DNA sequence and genomic instability (40).  How each pathway is activated in 
the cell is unknown, however, the requirement of HDR for a sister chromatid indicates a 
cell cycle component in the regulation of these pathways in which HDR is the primary 
pathway used during S and G2 (40).   
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 Repair of DSBs by NHEJ requires several steps to result in reformation of an 
intact DNA strand.  Like most DNA repair pathways, proteins required for NHEJ bind 
and recognize the DSB and lead to the recruitment of other proteins that coordinate their 
activities to result in a repaired piece of DNA (40).  The first proteins to bind are those 
that make up the DNA-PK (DNA-dependent protein kinase) heterotrimer, including the 
Ku70/80 heterodimer and DNA-PKcs (catalytic subunit) (40).  Following this step, DNA 
ends are processed by nucleases and polymerases including Artemis and XLF/Cernunnos 
and the ligase IV/XRCC4 complex ligates the DNA ends to reform the duplex DNA 
structure (40).  The intricacies of this process have let to be elucidated, but the basic 
mechanism of NHEJ has been delineated.     
 HDR is initiated by degradation of one strand on either side of a dsDNA break by 
nucleases followed by coating of the ssDNA region by RPA, which is known as DNA 
resectioning (42).  From this point, most of the subpathways involve invasion by the 
ssDNA region into regions of homology found elsewhere within the DNA, which is used 
as a template to synthesize DNA (42).  The DNA resynthesis step is accomplished by 
core resection machinery a component of which is the Mre11 complex, which is 
composed of Mre11, Rad50, and Nbs1 (42).  BRCA1, a tumor suppressor, functions as an 
ubiquitin ligase that polyubiquitinates CtIP, a ssDNA nuclease (42).  Both of these 
proteins are involved in HDR and are thought to play a role in mediating the DSB repair 
pathway choice of cells (43). 
 IR is widely used in the treatment of various cancers both as a single agent and in 
combination with other chemotherapies, including cisplatin (44).  Increased cellular 
sensitivity to IR following treatment with cisplatin has been described and is believed to 
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occur through decreased NHEJ (45).  Deficiencies in DNA-PKcs have been shown to 
lead to increased radiosensitivity in both cellular and mouse models (41, 46).  Also, cells 
with deficiencies in Rad52 (the yeast homolog of Rad50) show increased DSBs and 
cytotoxicity following exposure to ionizing radiation (41).  PARP, in addition to its role 
in BER, also plays a role in the recognition and repair of single-strand breaks, presenting 
the potential to increase cellular sensitivity to IR by PARP inhibition (47).  
 Defects in DNA repair pathways are frequently observed in cancer cells, which 
can be a factor in cancer development but also has the potential to be exploited 
therapeutically.  For instance, defects in BRCA1 and BRCA2 lead to decreased HDR and 
have been shown to increase sensitivity to PARP inhibition (48).  This scenario, referred 
to as “synthetic lethality” addresses the observed lethality that is induced by having a 
defect in two proteins, while a defect in either by itself does not induce lethality (48).  
Mutations in the BRCA1 gene have been shown to be a reliable predictive indicator of 
breast cancer development with carriers incurring a lifetime risk of 39-54% of 
development of epithelial ovarian cancer (EOC) (49).  BRCA1 has also been implicated 
in the progression of breast cancer as well as the response of these cancers to DNA 
crosslinking chemotherapeutic agents such as cisplatin, however resistance to these drugs 
continues to be a major limitation in disease treatment (50).  Determining the expression 
profile of tumor cells and correlating this to the response to various treatments is an 
ongoing endeavor in cancer treatment research.  For example, PARP inhibitors are 
currently being analyzed in the context of BRCA1 status, in order to induce an optimal 
cytotoxic effect.  This allows the possibility to increase patient response to 
chemotherapeutic treatment.  Inhibitors of other proteins such as DNA-PKcs have also 
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been developed and increase cellular sensitivity to IR both in vitro and in vivo and the 
potential exists that these studies will be expanded into the clinical setting to increase 
tumor sensitivity to IR (51). 
1.5.  Inhibition of Proteins Required for Genomic Maintenance and Stability  
 As described in previous sections, maintaining genomic stability is essential to 
prevent mutations and eventual disease acquisition.  A paradigm exists in which 
inhibition or disruption of the maintenance of genomic stability has deleterious 
consequences as seen in the acquisition of mutations and eventual development of 
disease; however inhibition of genomic stability in carcinogenic cells that have acquired 
uncontrolled growth potential could lead to decreased cell and tumor growth.  Several 
proteins involved in DNA repair and replication have already been targeted by small 
molecule inhibitors including PARP and topoisomerase II, however the long-term 
benefits of drugging these targets has yet to be realized, possibly due to the redundancy 
of function, leading to incomplete abrogation of cellular activity.  We hypothesize that 
targeting RPA and XPA presents a non-redundant mode of inhibition, as evidenced by 
the cellular effects of inhibiting these proteins as seen with siRNA and in disease states. 
1.5.1.  Replication Protein A (RPA) 
 Replication protein A (RPA) is a heterotrimeric single-stranded DNA (ssDNA) 
binding protein made up of 70, 34, and 14 kDa subunits (3).  RPA’s ssDNA binding 
activity is achieved though high-affinity interactions between 
oligonucleotide/oligosaccharide (OB) folds with DNA (52, 53).  Six OB-folds are found 
throughout the 3 subunits, four within p70, and one each in p32 and p14, however the  
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Figure 3.  Replication Protein A.  The three subunits of RPA are depicted.  OB folds are 
shown in yellow and the interdomain region of p70 is illustrated in red.   
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role of each of these OB-folds in binding to DNA has not been completely elucidated 
(Figure 3) (53).  The ssDNA binding activity of RPA is required for several DNA 
metabolic pathways including DNA replication, recombination and repair (3).  OB-folds 
in DNA binding domains A and B (DBD-A and DBD-B) in the central region of the p70 
subunit contribute most of the binding energy for RPA-ssDNA interactions (Figure 3) 
(52).  OB-folds contact DNA in two primary ways, through hydrophobic stacking of the 
bases with aromatic amino acids and by hydrogen bonding between side chains of the 
amino acids and the phosphate backbone (3).  These structural features make OB-folds an 
attractive target for the development of small molecule inhibitors (SMIs) of DNA binding 
activity.    
 Crystal structure analysis of DBD-A and DBD-B within RPA p70 bound to DNA 
revealed a conformational change in RPA when bound to an 8-nucleotide (nt) DNA 
substrate (Figure 4) (54).  However, the DNA binding activity of RPA is thought to 
extend beyond the central OB-folds of p70 because of the observation that there is a 50-
fold difference in the affinity of RPA for 30-nt vs. 10-nt DNA structures, despite the 
crystal structure indicating that the 8-nt DNA structure occupies almost the entire space 
of this domain (Figure 4) (3).  This implicates additional regions of RPA as being 
important for changing the dynamics of RPA-DNA interactions and there is some 
evidence of a contribution from DBD-D (within the p32 subunit) on RPA’s binding 
activity on longer substrates (3, 55, 55).  This was evidenced by a decrease in DNA-
binding activity when comparing WT RPA to RPA containing a missing DBD-D domain 
on DNA substrates 40-nt or longer (55).  However, studies looking at the ability of RPA 
p32 and p14 to bind DNA alone do not show significant DNA binding activity,  
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Figure 4.  Structure of RPA.  The crystal structure of RPA p70 from residues 181-422 
is represented in the absence (1A) or presence (1B) of a (dC)8 DNA substrate.  The 
structure was analyzed using PYMOL analysis of the PBD file 1FGU.  4A represents 
RPA in the open conformation in which it is unbound to DNA.  4B depicts RPA bound to 
the (dC)8 DNA substrate. 
  
A 
B 
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suggesting that the role of these subunits is structural in nature as opposed to contributing 
to DNA-protein interactions (56).   
 RPA has been shown to interact with different types of DNA, although it displays 
the highest affinity interaction with ssDNA (3).  RPA has also been shown to have DNA 
unwinding activity on oligonucleotides in which it is able to separate dsDNA into ssDNA 
(57).  This activity has been suggested to reside within the p70 subunit of RPA (58).  
RPA was first shown to interact with cisplatin-damaged DNA by Clugston and 
colleagues in 1992 and the involvement of RPA in the repair of cisplatin induced DNA 
damage was expanded upon the discovery that RPA preferentially binds to cisplatin 
damaged DNA compared to undamaged (59, 60).  RPA has also been shown to bind to 
UV-damaged DNA (3).  These interactions suggest that RPA is involved in 
discriminating damaged from undamaged DNA and implicates RPA in the damage 
recognition step of NER, in addition to suggesting that RPA is a potential factor in 
recognizing DNA damage during DNA replication. 
 RPA interacts with several proteins required for NER including XPA, XPG and 
XPF/ERCC1 (61, 61-64).  RPA has been shown to affect the activities of these proteins 
in vitro, for example, RPA increases the DNA binding activity of XPA as well as the 
endonuclease activity of XPG and XPF/ERCC1 (63, 64).  RPA has also been suggested 
to regulate the polarity of DNA strand binding by XPG 3' to the site of damage and 
XPF/ERCC1 5' to the site of damage (65).  These characteristics indicate that RPA does 
not only have a role in DNA binding, but also influences the activity of other proteins 
involved in NER, although how RPA is increasing this activity is not fully understood.  
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The potential exists that RPA acts as a scaffold to bring other proteins into close 
proximity to DNA or that RPA is affecting the activity of proteins directly.   
 RPA also interacts with proteins involved in DNA replication including DNA 
polymerase α (66).  Again, it is not clear what role these interactions play in replication, 
but it is possible that RPA binding to ssDNA acts as a scaffold to recruit proteins to the 
sight of replication and to participate in the formation of replication foci, allowing DNA 
replication to proceed (3).  In vitro studies demonstrate that RPA can influence the 
activity of both helicases and polymerases and may play a role in regulating polymerase 
fidelity during DNA replication (3).  Inhibition of the ssDNA binding activity of RPA has 
the potential to increase our understanding of the role of RPA in various pathways and to 
further elucidate the relationship between DNA binding activity and RPA’s role in 
regulating protein function.  In addition, targeting specific OB-folds found within RPA 
would allow the identification of the role each OB-fold is playing in RPA function. 
 Cancer cells are continuously progressing through the cell cycle, replicating their 
DNA and producing progeny cells.  The essential role of RPA in DNA replication can be 
exploited to specifically target highly proliferative cancer cells.  A molecularly targeted 
agent designed to inhibit the DNA binding activity of RPA would directly prevent its 
involvement in DNA replication and lead to reduced progression through S-phase and 
could ultimately result in the loss of cell viability.  In addition, inhibition of RPA has the 
potential to potentiate the effects observed with DNA damaging chemotherapeutic agents 
by inhibiting the repair of the damage, leading to persistent DNA damage that can 
potentially increase cytotoxicity. 
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  1.5.2.  Xeroderma Pigmentosum Group A 
 XPA is a 36 kDa zinc metalloprotein that appears to be exclusively involved in 
the NER pathway (Figure 5).  XPA participates in the initial steps in both GG-NER and 
TC-NER and is thought to play a role in recognizing bulky DNA damage due to its 
increased affinity for UV-damaged or cisplatin damaged duplex DNA compared to 
undamaged (67, 68).  The ability of XPA to interact with and recognize damaged DNA is 
thought to occur by deformation and local changes in the electrostatic potential of DNA 
that contains a bulky DNA lesion (69).     
 XPA is able to directly interact with several proteins in the NER pathway 
including RPA, ERCC1, and TFIIH and may play a role recruiting and stabilizing NER 
proteins.  The N-terminal portion of XPA (residues 4-97) has been shown to interact with 
the RPA p32 subunit and ERCC1 (70).  The C-terminal portion of XPA (residues 226-
273) has been shown to interact with TFIIH and the central domain (residues 98-219) 
represents the minimal DNA binding domain (MBD) and interacts with RPA p70 (70).  
The MBD domain also contains a zinc-binding domain which contains the sequence Cys-
X-X-Cys-(X)17-Cys-X-X-Cys which are Cys105, Cys108, Cys126, and Cys129, and is 
different from other typical zinc-binding DNA binding domains (70, 71).  The C-terminal 
domain contains several positively charged residues including Lys 141, Lys 145, Lys 
151, Lys 179, Lys 204 and Arg 207 (70).  This positively charged region has the potential 
to interact with the negatively charged DNA backbone.  Several glutamic and aspartic 
acid residues are also found within the central domain, which also have the potential to 
interact with the negative charged DNA backbone (70).  Although the crystal structure of 
XPA has not been resolved, the solution structure provides valuable information on  
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Figure 5.  NMR structure of XPA.  The solution structure of XPA (PDB code 1XPA) 
was visualized using PyMol.  Beta sheets are depicted in yellow, alpha helices are 
depicted in red and loop regions are depicted in white.  A zinc ion is represented by a 
white sphere. 
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XPA’s structure and potential interactions between XPA and DNA.  Further work has 
demonstrated that mutation of two conserved lysines, 141 and 179, to glutamate 
decreased cellular repair of UV-induced DNA lesions and decreased in vitro DNA 
binding activity (72).  Interestingly, mutation of residues that were not required for 
cellular repair of UV-induced lesions did inhibit XPA’s DNA binding activity, indicating 
that DNA binding alone is not responsible for NER of UV-induced DNA damage (72).  
In vitro analysis of XPA activity has also demonstrated that it can interact with both 
strands of a duplex cisplatin-damaged substrate and that it inhibits RPA-dependent DNA 
unwinding (73, 74).  These observations provide further insight into mechanistic roles for 
XPA in regulating NER. 
 Interactions between XPA and other proteins required for NER show a potential 
role for XPA in stabilizing and regulating NER proteins.  Inhibiting the DNA binding 
activity of XPA using small molecules is hypothesized to prevent XPA from participating 
in NER, leading to persistent DNA damage and resulting in increased cytotoxicity.  As 
previously discussed, the repair of cisplatin lesions by NER is thought to contribute to 
cellular sensitivity to this agent and by inhibiting proteins required for NER, the cytotoxic 
effect of cisplatin can potentially be increased.  Because XPA has not been demonstrated 
to play a role in cellular pathways beyond NER, inhibition of its DNA binding activity is 
expected not to possess single-agent activity and presents an opportunity to increase the 
cytotoxic activity of cisplatin without toxic effects from single-agent treatment. 
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1.6.  Chemotherapeutic Drugs   
1.6.1. Alkylating Agents 
 Nitrogen mustards are one of the earliest identified reagents to induce DNA 
interstrand crosslinks, which were recognized as a potential anti-cancer therapy due to 
their high reactivity with DNA (75).  Nitrogen mustards exert their cytotoxic and 
mutagenic effect by forming interstrand DNA crosslinks between guanine residues at the 
N7 atoms (75).  Because of the low specificity of these agents, their benefits as anti-
cancer treatments are limited.  Highly reactive molecules such as these are able to not 
only cause modification on the DNA, but may also form adducts on proteins, leading to 
deleterious cellular effects that may result in increased mutagenesis and the development 
of secondary cancers (75).  Despite these limitations however, nitrogen mustards have 
played a very important role in cancer treatment over the past decade (75).   
Temozolimide (TMZ) is an alkylating agent used in the treatment of cancers, 
particularly glioblastomas, that works by methylating adenine and guanine residues, 
causing them to mispair during DNA replication (76).  Typically the cell can repair the 
most cytotoxic lesion induced, 06 –methyl guanine, by direct reversal by 06 –
methylguanine methyltransferase (MGMT), and tumor response to TMZ treatment is 
correlated with the expression of MGMT (76).  However, if MGMT is underexpressed or 
inactive, cells can repair methylated residues using the BER pathway, indicating the 
importance in this pathway in cellular sensitivity to TMZ (23, 76).  Current studies 
examining the effect of PARP inhibition on TMZ sensitivity have been conducted and it 
was observed that PARP inhibition increases the anti-proliferative effect of TMZ, 
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indicating the importance of BER to repair lesions induced by TMZ, as well as the 
chemotherapeutic benefit of BER inhibition (77).  
1.6.2  Topoisomerase Inhibitors 
 Because of the essential role of DNA replication in cell proliferation, several 
chemotherapeutics have been developed to impede this pathway.  Topoisomerase I 
(topoI) has been the target of several chemotherapeutic drugs including camptothecin 
(CPT) and topotecan (78).  Topoisomerase II (topoII) has also been the target of 
inhibition by chemotherapeutic drugs including doxorubicin and etoposide (78).  
Etoposide induces its cytotoxic effect by interfering with the breakage and rejoining 
reaction that topo II uses to relieve DNA supercoiling during replication (79).  Etoposide 
interacts with topo II and traps a covalent reaction intermediate called the cleavable 
complex, which is believed to prevent the progression of DNA replication and ultimately 
induce apoptosis (79).  Although it is an effective chemotherapeutic agent, etoposide has 
very undesirable secondary effects manifested by the development of secondary cancers, 
including leukemia (80).   
 The mechanism of action by topo poisons is thought to be manifested not by 
direct inhibition of protein activity, but rather the stabilization of a covalent-DNA 
intermediate complex that blocks DNA replication from occurring but may also signal for 
repair (78, 79).  The repair of these lesions is thought to occur by the endonucleolytic 
activity of Flap-endonucleases including Mre11/Rad50 and XPF/ERCC1 due to the 
increased sensitivity to yeast strains to CPT when mutations in these proteins are made 
(78).  However, the exact repair mechanism of these lesions has not been elucidated and 
inhibition of DNA repair in general with, for example, RPA inhibitors, has the potential 
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to increase the cytotoxic activity of topoI and II poisons.  In addition, inhibition of RPA 
has the potential to potentiate the cytotoxic effects induced by etoposide due to dual 
inhibition of replication, both in initiation and elongation.   
1.6.3.  Cisplatin 
 The effect of platinum on cell survival was first observed by Dr. Barnett 
Rosenberg and colleagues in 1965 in which he observed elongation of E. coli cells, 
indicating an inability to divide, following exposure to an electric field (81).  Further 
analysis indicated that it was the platinum containing electrode that was responsible for 
this effect, as well as components of the buffer used to inoculate the bacteria, which 
included chloride and ammonia (81).  These studies were the first to characterize a 
cellular effect by platinum containing compounds and studies analyzing the effect of 
these compounds in cancer cells soon followed (82, 83). 
 Cisplatin, or cis-diamminedichloroplatinum (II), was one of the platinum 
containing compounds identified by these studies to have an anti-proliferative effect on 
tumor cells (83).  Cisplatin is composed of a central platinum ion that is coordinated with 
two cis-amine ligands as well as two cis-chloride ligands in a planar configuration (84).  
Intracellularly, a decreased chloride ion concentration favors hydration of the cisplatin 
molecule to form an aquated, more reactive form of cisplatin, [Pt(NH3)2Cl(OH2)]+ (84).  
Once aquated, cisplatin reacts with intracellular targets including both proteins and DNA, 
but its primary cellular target is thought to be DNA in which it binds covalently to 
guanine and adenine bases to form bulky adducts including 1,2 dGpG (65%), 1,2 dApG 
(25%) and 1,3 dGpNpG (5-10%) in addition to interstrand crosslinks (85, 86).  The 
formation of a cisplatin-DNA adduct induces a kink that disrupts normal DNA metabolic 
33 
 
processes including replication and transcription (86).  This disruption leads to activation 
of cellular processes that can result in removal of the cisplatin adduct and restoration of 
the DNA sequence, or, if the adduct is left unrepaired, the cell may undergo apoptosis.  
Since the first identification of cisplatin, several other derivatives of this compound have 
been analyzed for their antitumor activity, including oxaliplatin, carboplatin, and trans-
diamminedichloroplatinum(II), each of which varies in toxicity and activity (85, 87).   
 Currently platinum containing drugs containing are integrated into treatment 
regimens for late stage lung cancer patients (5, 88).  Although cisplatin is a front line 
therapy in the treatment of several cancers, efficacy varies significantly between patients 
causing a spectrum of responses.  The high mortality rate associated with lung cancer is 
indicative of the inadequate response of patients to chemotherapeutic treatment.  
Differences in the metabolism and uptake of cisplatin as well as the repair of cisplatin-
DNA lesions represent a few of the factors thought to influence cisplatin sensitivity.  
Several groups are currently examining the genotypic and proteomic differences between 
patients to determine if there are links between protein expression and response to 
chemotherapy.   
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2.  Small Molecule Inhibition of RPA and its Effect on DNA Replication and Repair 
2.1.  Introduction 
 The identification of small molecule inhibitors of proteins is a rapidly growing 
field in which researchers have undertaken screening small molecule libraries to identify 
compounds that display inhibition of protein activity.  These SMIs have the potential to 
decrease tumorigenic growth and impact numerous diseases.  The identification of 
proteins that are correlated with cancer development and response to treatment, such as 
the ras family of proteins, has led to the identification of many small molecules that 
inhibit protein activity, however successful integration of these molecules in a clinical 
setting has not always transpired (89, 90).  This is due to a number of factors including 
rapid adaptability of cancer cells as well as redundancy between pathways, leading to 
cellular compensation of protein inhibition.  The wide range of mutations incurred in 
different cancers along with the heterogeneous cellular population found within a single 
tumor contributes to tumor response to protein inhibition. The effect of tumor diversity is 
becoming more apparent as SMIs of proteins known to be misregulated in cancer often 
do not have the desired effect on tumor development and response to chemotherapeutic 
treatment (89).  Recent hypotheses on the development of anti-cancer agents has lead to 
the suggestion that inhibiting proteins important for maintaining genomic stability may 
be an effective way to perturb tumorigenic growth (91).  Although all tumors are 
distinguished by differences in protein mutations, all cancers are defined by having some 
deficiency in maintaining genomic stability (91).  Inhibition of proteins essential for this 
process may prove to be a means of globally preventing cancer development and 
proliferation and has the potential for widespread utility in cancer treatment.   
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The essential requirement of RPA for DNA replication and repair suggests the 
effect of inhibiting this protein will be a reduction of the ability of any rapidly dividing 
cell to proliferate and to repair DNA damage that requires RPA.  This presents the 
opportunity for single-agent activity of inhibition of RPA in addition to the potential 
utility of combination therapy integrating RPA inhibition in conjunction with DNA 
damaging chemotherapeutics.  Using a novel high-throughput screen, we have identified 
a class of SMIs of RPA and present the characterization of one of these compounds, 
TDRL-505, which shows in vitro inhibitory activity of RPA’s DNA binding activity in 
addition to single agent cytotoxic activity in NSCLC cell lines.  TDRL-505 shows 
synergistic cellular activity with cisplatin and etoposide and presents the first 
identification of a small molecule that inhibits the DNA-binding activity of a protein. 
2.2.  Materials and Methods 
2.2.1.  Materials 
Oligonucleotides were purchased from Integrated DNA Technologies, Inc. 
(Coralville, IA).  Vybrant Apoptosis Assay Kit was purchased from Invitrogen.  
Cisplatin, etoposide, aphidicolin, propidium iodide (PI) and 5-bromo-2'-deoxyuridine 
(BrdU) were obtained from Sigma Chemical Co. and nocodazole was obtained from 
Calbiochem.  RPMI 1640 containing L-glutamine (Mediatech) was supplemented with 
10% fetal bovine serum (FBS) and 1% penicillin/streptomycin.  H460 and A549 cells are 
from ATCC and maintained in RPMI.  All small molecule inhibitors were obtained from 
ChemDiv (San Diegeo, CA) and resuspended in 100% dimethylsulfoxide (DMSO) at a 
final concentration of 10 mM and stored at -20°C.  Dulbecco’s phosphate buffered saline 
(PBS) was obtained from Gibco.  α-RPA primary antibody was obtained from 
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NeoMarkers and goat α-mouse secondary antibody was obtained from Santa Cruz 
Biotechnology. 
2.2.2.  Chemicals  
 Cisplatin was prepared at a concentration of 1 mM by dissolving into dH2O and 
stirring for 1 hour.  The solution was then sonicated for 10 minutes at 60% power after 
which 1 mL aliquots were stored at -20°C.  BrdU was prepared at a concentration of 20 
mM in dH2O and stored at -20°C.  Etoposide was dissolved in DMSO at a final 
concentration of 50 mM and stored at -20°C.  Nocodazole was resuspended in DMSO to 
a final concentration of 5 mg/mL and stored at room temperature.  Aphidicolin was 
resuspended in 100% EtOH and stored at 4°C.  PBS-ethylenediaminetetraacetic acid 
(EDTA) was prepared at 9.6 mg/mL PBS with 0.8 mM EDTA.  PI was dissolved at a 
final concentration of 1mg/mL in dH2O and stored at 4°C. 
2.2.3.  DNA Substrates 
All ssDNA substrates were gel purified on preparative 12% denaturing 
polyacrylamide gels.  Briefly, DNA was electrophoresed at 280 volts for 3 hours and 
visualized by UV-shadowing.  Bands were cut from the gel and eluted overnight with 
rotation at 4°C in 3 mL of elution buffer (0.3M NaOAc, 1 mM EDTA and 0.1% SDS).  
The DNA was then EtOH precipitated with 9 mL of -20°C 100% EtOH, 0.3 M NaOAc, 
and 1 µg/mL glycogen with incubation at -80°C for one hour.  DNA was then sedimented 
at 7800 x g for 45 minutes, the pellet resuspended in dH2O and concentration determined 
by absorbance reading at 260 nm.  For specific DNA sequence information, see 
Appendix A. 
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2.2.4.  RPA Purification 
Heterotrimeric RPA was purified by transforming BL21 (DE3) competent cells 
with p11-tRPA plasmid DNA provided by Dr. Marc Wold (56).  Cells were incubated 
overnight at room temperature without shaking and then at 37°C with shaking until cells 
gave an absorbance reading of 0.8 at A600.  Protein expression was then induced with 
IPTG with shaking and incubation at 37°C for two hours.  Cells were then harvested by 
centrifugation at 700 x g for 30 minutes at 4°C.  The pellet was resuspended in 10 mL H1 
buffer (30 mM Hepes, 1 mM DTT, 0.25% myo-inositol, and 0.1% NP-40, with a protease 
inhibitor mix (containing 1µg/mL phenylmethanesulfonylfluoride (PMSF), aprotinin, 
leupeptin, and pepstatin)) and sonicated at 60% power 3 x 30 seconds with 30 second 
pauses between pulses.  The lysate was then sedimented at 11,200 x g for 30 minutes at 
4°C.  The supernatant was loaded over a 20 mL Blue Sepharose column, which was 
washed in 0.1 M NaOH and 1 M NaCl and then equilibrated with H1 buffer with 0.1 M 
KCl, at 1 mL/min.  Following loading of the column, it was washed with H1 buffer with 
0.1 M KCl, H1 Buffer with 0.8 M KCl, and H1 buffer with 0.5 M NaSCN at 1 mL/min.  
After washing, the protein was eluted into 10 mL fractions with H1 Buffer containing 1.5 
M NaSCN.  Protein containing fractions were identified using Bradford analysis, pooled 
and loaded directly onto a 5 mL hydroxyapatite (HAP) column equilibrated in H1 buffer.  
The sample was loaded at 2 mL/min and the column was washed with H1 buffer.  H1 
Buffer with 0.1 M KPi was used to elute the protein off of the column in 5 mL fractions.  
Protein containing fractions were identified using Bradford analysis, pooled, and loaded 
onto a 5 mL Q-sepharose column, equilibrated in 0.1 M KCl, at 2 mL/min.  The column 
was washed with H1 buffer with 0.1 M KCl and protein was eluted using a gradient from 
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0.1 M to 1 M KCl and fractions containing RPA were identified using Bradford and SDS-
PAGE analysis, pooled and dialyzed overnight at 4°C in H1 buffer (Figure 8A). 
2.2.5.  High-Throughput Screening  
A small molecule library of compounds from ChemDiv was screened as described 
in Turchi et al. (92).  Briefly, 60 nM RPA and 10 nM fdT12 DNA were mixed in binding 
buffer (20 mM Hepes, 1 mM DTT and 0.01% NP-40) and then aliquoted into 384 well 
plates containing 10 µM of each compound in a final volume of 50 µL.  Fluorescence 
anisotropy was used to determine inhibition of RPA binding to DNA as described in 
section 2.2.7.  Positive hits that significantly inhibited RPA-DNA interactions were 
identified and obtained from ChemDiv.    
2.2.6.  Electrophoretic Mobility Shift Assays (EMSAs) 
EMSAs were performed in 20 µL reactions, unless otherwise indicated, 
containing 5′ [P32] labeled DNA and protein as indicated in the Figure legend.  EMSAs 
examining protein binding to DNA were performed by incubating protein and DNA for 5 
minutes at room temperature in RSSE buffer (20 mM Hepes, 1 mM DTT and 0.01% NP-
40).  For EMSAs examining compound inhibition of protein binding to DNA, protein 
was pre-incubated with compound in RSSE buffer for 5 minutes at room temperature.  
Compounds were diluted from 10 mM stocks in 100% DMSO to 0.5 mM in 10 µM 
Hepes and 10% DMSO.  Following pre-incubation, DNA, RSSE buffer and agarose dye 
(10% glycerol, 10 mM EDTA, 0.01% xylene cyanol and 0.01% bromophenol blue) were 
added to the reactions which were incubated for an additional 5 minutes at room 
temperature.  Samples were loaded onto a 6% native polyacrylamide gel and 
electrophoresed at 170 volts for 1 hour.  Gels were then dried and exposed to a 
39 
 
PhosphoImager screen (Molecular Dynamics) for 30 minutes.  The screen was then 
scanned using a Storm 820 (Amersham Biosciences) and quantified using ImageQuant 
software (Molecular Dynamics).  The results presented indicate the average and standard 
deviation from at least 3 individual experiments.  The IC50 values were calculated using 
Sigma Plot with fitting to the appropriate decay curve.   
2.2.7.  Fluorescence Anisotropy 
 Anisotropy based binding assays were performed in a volume of 500 µL in RSSE 
buffer containing protein and 5′ fluorescein-labeled DNA as indicated in the Figure 
legend.  10 nM DNA was mixed with buffer in each reaction and fluorescence read using 
a Cary Eclipse fluorescence spectrophotometer.  Fluorescence was read at 515 nm 
following excitation at 495 nm with vertical and horizontal polarizers.  Slit widths were 
each set at 5 nm and voltage was typically 800 volts.  For reactions containing TDRL-505 
and protein, reactions were pre-incubated with binding buffer in a final volume of 500 µL 
for 2 minutes after which precipitate was removed by spinning at 9300 x g for 10 
minutes.  The supernatant was then mixed with DNA and fluorescence was read.  The 
final concentration of DMSO in each 500 µL reaction was 0.5%.  The fluorescence 
anisotropy values (r) were calculated using the equation (r) = Iv-Ih/Iv + 2Ih (equation 
2.1).  The results indicate the average and standard deviation from at least 3 individual 
experiments.  The IC50 value was calculated using Sigma Plot with fitting to the 
appropriate decay curve. 
2.2.8.  Crystal Violet Cell Viability Assays 
Cell viability assays were performed using a modified version of the protocol 
described (Van SS, Mol. Cancer Ther, 2006).  H460 NSCLC cells were seeded at 1 x 104 
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cells/cm2 in 6-well plates.  Cells were incubated for 24 hours at 37°C and then treated 
with increasing concentrations of TDRL-505 (in a final concentration of 1% DMSO) or 
vehicle (1% DMSO) for 48 hours at 37°C.  After treatment, cells were trypsinized and 
resuspended in 1 mL media.  10 µL of resuspension was replated onto a 24-well plate in 
triplicate and grown for 5 days at 37°C.  Wells were then washed with PBS and stained 
with crystal violet solution (0.75% Crystal Violet in 50% EtOH with 0.125% NaCl and 
0.88% Formaldehyde) for 10 minutes.  Following staining, cells were washed in dH2O 
and the dye resolubilized with 1% SDS in PBS.  Absorbance was read at 595 nm using a 
SpectraMax M5 spectrophotometer (Molecular Devices).  The results are presented as the 
average and standard deviation from at least 3 individual experiments and the IC50 value 
was calculated using Sigma Plot with fitting the appropriate decay curve.  
2.2.9.  Cell Cycle Analysis 
H460 NSCLC cells were plated at a density of 1 x 104 cells/cm2 for 24 hours and 
then treated with increasing concentrations of TDRL-505 (at a final DMSO concentration 
of 1%) or vehicle (1% DMSO) for 48 hours as indicated.  Following plating and 
treatment of H460 cells, adherent and non-adherent cells were collected and sedimented 
by spinning at 170 x g for 5 minutes and then washed twice with 1% bovine serum 
albumin (BSA) in PBS-EDTA.  Cells were fixed in 70% EtOH at -20°C followed by 
incubation on ice for 30 minutes following which cells were pelleted at 170 x g for five 
minutes and stained with 1 µg/mL propidium iodide (PI) and 25 µg/mL RNaseA for 1.5 
hours.  PI stained cells were then analyzed on a Becton Dickinson FACScan flow 
cytometer (BD Bioscience, San Jose, CA).  Cells were gated and analyzed on a histogram 
with events plotted against the FL2-A parameter.  Cell cycle distribution was analyzed 
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using ModFit software (Verity Software House, Topsham, ME).  To determine the effect 
of TDRL-505 on entry into S-phase, G2 arrest was induced by treatment with 0.8 µg/mL 
nocodazole for 12 hours (93).  Cells were then washed with PBS and treated with either 
vehicle or TDRL-505 (100 µM) for various times as indicated.  Cells were harvested and 
analyzed for cell cycle distribution as described above.  The results presented indicate the 
average of at least 3 individual experiments.   
2.2.10.  Analysis of BrdU Incorporation 
To analyze incorporation of 5-Bromo-2′-deoxyuridine (BrdU) into cellular DNA, 
H460 NSCLC cells were plated at a density of  1 x 104 cells/cm2 for 24 hours and then 
treated with 0.8 µg/mL nocodazole for 12 hours to induce a G2 cell cycle arrest (93).  
Following induction of G2 arrest, cells were treated with vehicle or 100 µM TDRL-505 
for 8 or 12 hours as indicated in the Figure legend.  Two hours prior to harvesting, cells 
were labeled with 10 µM BrdU after which adherent cells were trypsinized and pelleted 
at 170 x g for 5 minutes.  Cells were then washed with PBS-EDTA, pelleted at 170 x g 
for 5 minutes and fixed in 1 mL 70% EtOH (-20°C) while vortexing.  Following fixation, 
DNA was denatured with 0.5 mL 2 M HCl for 20 minutes at room temperature, washed 
with wash buffer (PBS with 0.5% BSA) and pelleted at 170 x g for 5 minutes. The HCl 
was then neutralized with 0.5 mL 0.5 M sodium borate for 2 minutes to which 1 mL wash 
buffer was added and cells were pelleted at 170 x g for 5 minutes.  Cells were then 
incubated with 50 µL mouse anti-BrdU antibody (CalBiochem) diluted 1:500 in dilution 
buffer (PBS with 0.5% Tween-20 and 0.5% BSA) for 20 minutes at room temperature, 
washed with wash buffer, pelleted and then incubated with 50 µL AlexaFluor 488 goat 
anti-mouse secondary antibody (Invitrogen) (1:500 in dilution buffer) for 20 minutes at 
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room temperature.  Following antibody incubation, cells were washed, pelleted and then 
incubated in 1 µg/mL PI in PBS-EDTA for at least 30 minutes at 4°C.  Cells were then 
analyzed using flow cytometry (as described in 2.2.9) for cell cycle and BrdU staining 
using FLA and FL1 parameters, respectively.   
2.2.11.  Annexin V/PI Staining  
H460 cells were plated at a density of 1 x 104 cells/cm2 for 24 hours and treated 
for 48 hours with increasing concentration of TDRL-505.  Following treatment, cells 
were analyzed for apoptosis using an Annexin V-FITC/PI Vybrant Apoptosis Assay Kit 
(Invitrogen), according to manufacturer’s instructions.  Briefly, adherent and non-
adherent cells were collected and pelleted at 170 x g for 5 minutes.  Cells were then 
washed with PBS-EDTA and resuspensded in 100 µL of 1x Annexin V binding buffer 
(10 mM Hepes, 140 mM NaCl, 2.5 mM CaCl2, pH 7.4).  PI was added to a final 
concentration of 1 µg/mL along with 5 µL of the Annexin V conjugate dye.  Cells were 
then incubated for 15 minutes at room temperature after which 400 µL of 1x Annexin V 
binding buffer was added.  A minimum of 1 x 104 cells were analyzed for each sample on 
a BD FACScan flow cytometer using FL1 and FL2 parameters.  Data was analyzed using 
WinMDI version 2.8 software (http://facs.scripps.edu/software.html, 1-19-00).  A549 
cells were plated and treated as described for H460 cells.  The results indicate the average 
and standard deviation of at least 3 individual experiments (H460s).  IC50 values were 
determined using Sigma Plot with fitting to the appropriate decay curve.  
PBMCs were isolated from whole blood using a Ficoll purification protocol.  
Whole blood was collected and diluted with an equal volume of PBS and then applied to 
a 15 mL conical tube containing ~4 mL of ficoll being careful not to mix the two.  The 
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sample was then sedimented at 400 x g for 35 minutes at -20°C with no brake and no 
acceleration.  Following sedimentation, red and polynuclear cells were retained in the 
ficoll layer and PBMCs were confined to the interface between the blood layer and ficoll 
layer.  The interface layer containing PBMCs was removed and diluted with 10x volume 
of PBS and sedimented at 300 x g for 10 minutes.  The cells were then resuspended in 10 
mL of media and plated onto 10 cm dishes.  Cells were then treated immediately as 
described for H460s and harvested and analyzed by flow cytometry at 24 and 48 hour 
time points as described for H460 cells.   
2.2.12.  Indirect Immunofluorescence 
H460 cells were plated on chamber slides (LabTek) at a concentration of 40 
cells/µL in 500 µL and allowed to adhere for 24 hours.  Cells were then treated for 3 
hours with either 50 µM TDRL-505 or vehicle as indicated in the Figure legend.  To 
determine the effect of etoposide on RPA foci formation, cells were treated for 4 hours 
with either 50 µM TDRL-505 or vehicle, as indicated, in the presence or absence of 25 
µM etoposide.  Following treatment, cells were fixed in 4% paraformaldehyde at 25°C 
for 3 minutes followed by incubation with 0.2% Triton X-100 for 2 minutes at 4°C.  The 
slides were then blocked in blocking buffer A (15% FBS in PBS-EDTA) for 1 hour at 
25°C and then incubated with mouse anti-RPA p34 primary antibody (Neomarkers) 
(1:500) in blocking buffer A for 1 hour.  Slides were then washed 3 x 10 minutes with 
blocking buffer A and incubated with Alexa Fluor-594 goat-anti-mouse secondary 
antibody (Invitrogen) (1:300) in blocking buffer A for 1 hour.  Slides were again washed 
with blocking buffer A and stained with 300 nM DAPI diluted in PBS-EDTA for five 
minutes.  Slides were then mounted and images captured using a Zeiss fluorescent 
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microscope using filters for Texas Red to visualize RPA staining and 4′,6-diamidino-2-
phenylindole (DAPI) for visualizing DNA.  Slides were visualized and images analyzed 
and quantified using ImageJ software (http://rsb.info.nih.gov/ij/index.html, 2-12-10).   
2.2.13.  Western Blot Analysis 
 H460 cells were plated at a density of 1 x 104 cells/cm2 in 10 cm dishes for 24 
hours then treated with either vehicle (1% DMSO) or increasing concentrations of 
TDRL-505 for 8 hours as indicated in the Figure legend.  Following treatment, adherent 
cells were scraped with 100 µL RIPA buffer (150 mM NaCl, 10 mM Tris pH 7.2, 0.1% 
SDS, 1% Triton X-100, 1% deoxycholate, 5 mM EDTA and 1 µg/mL PMSF, aprotinin 
and pepstatin) and incubated on ice for 10 minutes with vortexing at 2 minute intervals.  
Samples were then spun at 10,000 x g for 10 minutes at 4°C and supernatant removed.  
Protein concentration was determined using Bradford analysis and ~45 µg of total protein 
was electrophoresed on a 12% Bis-Tris SDS-PAGE gel (Invitrogen) in 2-(N-
Morpholino)ethanesulfonic acid (MES) buffer at 200 volts for 1 hour.  The gel was then 
transferred to a PVDF membrane activated with methanol at 30 volts for 1 hour in 
NuPage transfer buffer (Invitrogen) and then blocked in blocking buffer B (2% BSA-
TBS-Tween (0.5% Tween-20, 20 mM Tris, pH 7.5, and 0.17 M NaCl)) for 1 hour.  RPA 
was detected with a mouse anti-RPA p34 antibody (Neomarkers) diluted to 1:3000 in 
blocking buffer B for 1 hour.  The blot was then washed 3 x 5 minutes in TBS-Tween 
followed by a goat anti-mouse secondary antibody (Santa Cruz Biotechnologies) diluted 
to 1:5000 in blocking buffer B.  The blot was then washed 3 x 5 minutes in TBS-Tween 
and protein was visualized using chemiluminescence reagent (0.1 M Tris, pH 8.5, 1.25 
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mM Luminol, 0.18 mM p-coumaric acid and 0.03% H2O2) followed by exposure using a 
Fuji LAS-3000 system (Tokyo, Japan). 
2.3.  Results 
Identification of Small Molecule Inhibitors from High-Throughput Screen 
 In order to identify novel small molecule inhibitors of RPA, an in vitro high-
throughput screen of a small molecule library of compounds from ChemDiv was 
conducted.  A fluorescence-based high-throughput assay was employed, measuring 
inhibition of RPA binding to fluorescein-labeled DNA.  Our assay yielded a z-score of 
0.8 (92).  Initial screening of approximately 42,000 compounds identified 54 that 
inhibited RPA from binding to DNA (92).  In order to confirm the inhibitory activity of 
compounds identified from the primary screen, we used non-spectroscopic EMSA assays 
to minimize false positives due to the spectral characteristics associated with many of the 
compounds.  Secondary screening analysis revealed two compounds that displayed 
significant inhibition of RPA-DNA binding activity in vitro (compounds 3 and 5) (Figure 
6A).  Compound 3 consists of a tri-substituted pyrazole ring with an oxo-butanoic acid at 
N1, a p-methyl benzene ring at the C3 position, and a 7-ethoxyquinolin-2(1H)-one at the  
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Figure 6.  Identification of SMIs of RPA.  6A.  EMSA analysis of compounds 
identified from the high-throughput screen performed for RPA.  25 nM RPA was 
incubated with 100 µM of each compound for five minutes to which 25 nM SJC 1.5 Xba 
(34-nt) DNA was added and incubated an additional 10 minutes.  Samples were then 
electrophoresed on polyacrylamide native gels as described in section 2.2.6.  6B.  EMSA 
analysis of compound 3 like small molecules.  Reactions were performed and analyzed as 
described in 6A.   
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C5 position (Figure 7A).  Compound 5 consists of a benzoic acid containing a 6-methoxy 
cyclopenta[c]quinoline at the C4 position (Figure 7B).  
As in vivo inhibition of RPA using siRNA has been shown to be cytotoxic due to 
its critical role in DNA metabolic processes, we analyzed the effect of compounds 3 and 
5 on NSCLC cell viability (94).  While no cellular effect was seen with compound 5, 
limited cellular activity of compound 3 was observed, however these analyses were 
hampered by poor solubility.  Considering the high level of in vitro inhibition observed 
with compound 3, we retained a core structure consisting of a substituted 
dihydropyrazole with a 4-oxo-butanoic acid at N1 and a phenyl substituent at C3 to 
initiate analysis of structure activity relationships (SAR) and identify compounds with 
cellular activity (Figure 7C).    
Structure-Activity Relationship Studies of Compound 3 like Molecules 
Structure-activity relationship (SAR) studies were performed by retaining the core 
structure described in Figure 7C and searching the ChemDiv library to identify small 
molecules containing this core structure.  Eighty-one analogs were identified and 
obtained from ChemDiv with differing substitutions off the phenyl ring (R2) and varying 
substituents at position C5 on the dihydropyrazole ring (R1) (Figure 7C).  These 
derivatives were analyzed for in vitro RPA inhibitory activity using EMSAs (Figure 6B 
and data not shown).  A subset of these compounds that showed the ability to inhibit 
RPA’s DNA binding activity were further characterized to determine how the structure of 
each contributes to inhibition of DNA binding activity.  Using EMSA analysis, titrations 
of each compound were performed and the IC50 of each was determined.  Among the  
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Figure 7.  Structures of SMIs of RPA.  7A.  Structure of compound 3, identified from 
the HTS for SMIs of RPA.  7B.  Structure of compound 5, also identified from the HTS 
for SMIs of RPA.  7C.  The core structure of compound 3 retained for searching the 
ChemDiv library.  7D. Structure of TDRL-505. 
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compounds analyzed, TDRL-505, consisting of a methoxy quinolone at the R2 position 
and bromine at the R1 position, was the most potent inhibitor with an IC50 of 13 µM 
(Figure 7D and Table 2).  TDRL-520-523 also contain a bulky substituent at the R1 
position, however, these compounds contain a di-substituted pyrazole ring and show 
varying capacities for inhibiting RPA-ssDNA interactions (Table 2).  Interestingly, 
TDRL-518, which does not inhibit RPA’s DNA binding activity in vitro, retained the 
initial core structure associated with compound 3; however it contains a diethyl amine 
group at the R1 position that has the potential to be positively charged at neutral pH.  
This group is not expected to interact with the positively charged arginines and lysines 
found in the RPA OB-folds that are responsible for interaction with negatively charged 
DNA, which is a potential explanation for the lack of inhibition observed with this 
compound.  Compound 523 also did not display inhibition of RPA-DNA interactions and 
contains a di-substituted pyrazole with a methoxy group at the C3 position of the benzene 
ring.  Compounds 518 and 523 do not show significant in vitro activity, however, how 
the structures of these compounds influence this activity is not known.  As the quinoline 
substitution had the most potent in vitro activity, we analyzed the structures of all 
compounds obtained in the analogy search with this substituent.  Three additional 
compounds were identified; however, their analysis was hampered by similar insolubility 
issues as observed for compound 3.   
We then analyzed cellular activity of the 6 compound 3 like molecules shown in 
Table 2 in H460 cells and calculated IC50 values for each compound following a 48 hour 
exposure using Sigma Plot with fitting to the appropriate decay curve.  A correlation 
between in vitro and cellular activity, consistent with cellular inhibition of RPA was  
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Table 2. 
Structure activity relationships of small molecule RPA inhibitors  
Name Structure             IC50 (µM)  
  In vitro Cellular 
TDRL-505 
 
12.9 ± 1.3 30.8±1.7 
TDRL-518 
 
    >100* NA 
TDRL-520 
 
20.3±10.7 49.9±2.5 
TDRL-521 
 
71.7±33.9 56.9±6.7 
TDRL-522 
 
56.1±6.7 38±32*** 
TDRL-523 
 
    >100** 31.0±5.2 
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Table 2.  In vitro and Cellular IC50 values for Compound 3 like small molecules. 
The in vitro IC50 was determined by EMSA analysis as described in Figure 6A. Cellular 
IC50 was determined by treating H460 cells and analyzing annexinV/PI staining as 
described in section 2.2.6.  The in vitro and cellular data was analyzed using standard 4 
parameter logistic curves.  The IC50 values and standard error of the fit were determined 
from this analysis using Sigma Plot with fitting to the appropriate decay curve. 
*inhibition at the highest concentration tested (100 µM) was 9% 
**inhibition at the highest concentration tested (100 µM) was 36% 
*** Maximum observed cytotoxicity was 80% of control 
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observed.  Interestingly, compound 523, which showed minimal inhibition of RPA in 
vitro, did display modest cellular activity, which could be attributed to metabolism or 
other cellular effects.  After analysis of the cellular and in vitro inhibitory activity of 
compound 3 analogs, TDRL-505 displayed the lowest in vitro IC50 and was the most 
potent compound of those examined in cells.  We therefore selected this compound to 
further investigate its mechanism of action and the cellular effects that result from 
inhibition of RPA-ssDNA interactions using a comprehensive series of in vitro and cell 
based assays.    
In vitro Analysis of TDRL-505 
RPA binding to synthetic oligonucleotide substrates has been well characterized 
with respect to structural features and kinetics of binding (54, 74, 95, 96).  In order to 
determine the potential mode of binding and inhibitory activity of TDRL-505, inhibition 
of RPA by TDRL-505 was examined on various DNA substrates.  A 34-base purine rich 
substrate (SJC 1.5 Xba, Appendix A) was used to examine inhibition of RPA-DNA 
interactions using EMSA analysis.  The purine-rich substrate allows for a true 
equilibrium between free RPA and RPA-DNA complex to be achieved, which is essential 
when examining a competitive binding reaction.  Pyrimidine-rich sequences of this length 
display an extremely slow rate of dissociation from RPA which limits their utility in 
competitive binding reactions (96).  This length of DNA is also capable of extending 
beyond DBD-A and DBD-D OB folds of RPA p70 to allow interactions with the other 
OB-folds within p70 as well as the p34 and p14 subunit.  This analysis has the potential 
to provide information about where the compound interacts with RPA.  TDRL-505 was 
titrated with 25 nM RPA in the presence of 5′-[32P]-labeled 34-base purine-rich ssDNA.   
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Figure 8.  In Vitro Analysis of TDRL-505.  8A.  Wild-type RPA purification SDS-gel.  
RPA was purified as described in section 2.2.4.  The lanes represent as follows:  1-Low 
molecular weight marker, 2-Whole cell extract, 3-Pooled fractions, blue sepharose 
column, 4-Flow through, blue sepharose column, 5-Pooled fractions, HAP column, 6-
Flow through, HAP column, 7-Pooled fractions, Q column.  8B.  Analysis of TDRL-505 
on RPA DNA binding activity.  25 nM RPA was incubated with increasing 
concentrations of TDRL-505 for five minutes at room temperature to which 25 nM SJC 
1.5 Xba (34-nt) DNA was added for an additional five minutes.  Samples were 
electrophoresed on a native polyacrylamide gel as described in section 2.2.6.  8C. 
Quantification of 8B.  The data was fit to a standard 4 parameter logistic curve with an 
n=4.  8D.  Anisotropy analysis of RPA binding to a dT12 DNA substrate.  The data was fit 
to a standard 4 parameter logistic curve with an n=3.   
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Analysis of binding in an EMSA using the 34-base purine-rich sequence revealed a 
concentration dependent decrease in binding with an IC50 of 13 µM, as determined by 
Sigma Plot analysis (Figure 8B and 8C).   
To further define the mechanism of inhibitory action of TDRL-505, we assessed 
binding to poly-T ssDNA 12 bases in length (dT12).  The length of this DNA substrate 
largely restricts binding to DBDs A and B, which has been shown in the co-crystal 
structure of RPA p70 (amino acids 183-420) with a short oligonucleotide, to interact with 
DNA (54).  The sequence was modified to be pyrimidine-rich (dT12) because of a 
relatively fast off rate of RPA for a substrate of this length.  The faster on-rates of RPA 
for pyrimidine-rich DNA can compensate for the decrease in affinity associated with the 
shorter length to allow detection (96).  A fluorescence polarization (FP) based anisotropy 
assay was used in the analysis of the dT12 substrate as the lengthy electrophoretic 
separation associated with EMSA analysis is detrimental to accurately analyze inhibition 
of binding to this substrate.  RPA binding to a 34-base purine-rich sequence does not 
display the same high rate of dissociation that is seen with dT12, which allows this 
substrate to be used in EMSA analysis.  Titration of TDRL-505 resulted in a 
concentration dependent decrease in RPA binding and an IC50 value of 20.4 µM (Figure 
8D).  The fact that TDRL-505 still displays robust inhibition on the short 12 base 
substrate strongly suggests that the compound is targeting the central p70 OB-folds 
(DBD-A and -B).   
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TDRL-505 induces cytotoxicity in a NSCLC cell model 
 Having determined the in vitro inhibitory activity of TDRL-505 on RPA-DNA 
interactions, we sought to determine the mechanism of cellular activity of this compound. 
The effect on cell viability was determined using two independent assays presented in 
Figure 9.  The induction of apoptosis was assessed via a flow cytometric based assay 
measuring propidium iodide (PI) uptake, which is a DNA intercalating agent that 
indicates a loss of membrane integrity, and annexin V staining of extracellular membrane 
bound phosphotidylserine, an early step in the initiation of apoptosis (Figure 9A).  H460 
NSCLC cells were treated with increasing concentrations of TDRL-505 for 48 hours, 
after which annexin V/PI staining was performed.  The results demonstrate minimal 
annexin V staining suggesting that classical apoptosis was not occurring as a result of 
treatment (97).  Interestingly, a concentration dependent increase in PI staining was 
observed, indicating a general loss of membrane integrity.  Quantification of the viable 
cells (annexin V negative/PI negative) resulted in an IC50 of 30.8 µM as determined by 
Sigma Plot analysis (Figure 9B).  The PI positivity in the absence of annexin V positivity 
is suggestive of necrotic cell death which has been observed in other cell models (98).  
As an independent measure of the effect of TDRL-505 on cell viability, we employed a 
crystal violet based assay modified from a previously published protocol (99).  H460 
cells were treated with increasing concentrations of TDRL-505 or vehicle for 48 hours, 
trypsinized and replated in the absence of compound.  Cultures were then grown for five 
days and stained with crystal violet, washed, solubilized and quantified by measuring 
absorbance at 595 nm.  Treated cultures were compared to a mock treated control and 
results presented as the percent of viable control cells.  The data obtained reveal a  
56 
 
 
 
Figure 9.  Cellular analysis of TDRL-505.  9A.  H460 cells were treated for 48 hours 
with increasing concentrations of TDRL-505 as indicated in the Figure.  Cells were then 
analyzed for Annexin V and PI content, represented by the x- and y-axis, respectively, 
using flow cytometry.  Viable cells (Annexin V-/PI-) were determined to be those present 
in the lower left quadrant.  9B.  The data from 3A was quantified and the percentage of 
untreated cells that did not stain with either dye (present in the lower left quadrant), 
indicating live cells, calculated. The average and standard deviation from 4 replicates are 
presented and the data fit to a 4-parameter logistic curve.  The average IC50 of TDRL-505 
in this treatment was determined to be 30.8 µM.  9C.  H460 cells were analyzed for cell 
viability using crystal violet assays as described in section 2.2.8.  The results represent 
the averages from 3 independent experiments that were fit to a 4-parameter logistic curve 
and are presented as the percentage of vehicle treated control cells.   
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significant reduction in cell viability with an estimated IC50 of 64 µM (Figure 9C).  The 
similarity of cellular activity observed in the crystal violet analysis compared to that seen 
with the annexin V/PI staining suggests that the extent of PI staining is indicative of a 
true loss of cellular viability following treatment with TDRL-505.  A similar result was 
also observed following treatment of A549 NSCLC cells with TDRL-505 (Figure 10).  
To determine if TDRL-505 displays selectivity for cancer cells, its effect was examined 
on a culture of freshly isolated non-cancerous peripheral blood mononuclear cells 
(PBMCs).  After 24 hours of treatment, the cells showed a modest sensitivity to the 
compound compared to H460 cells with cell viability decreased by 50% at 100 µM of 
TDRL-505 compared to a greater than 90% loss of viability seen with H460 cells after 24 
hours of treatment (Figure 11).  Analysis of the 48 hour time point was not possible as a 
result of the inherent loss of PBMC viability with extended culture times.  Therefore, 
TDRL-505 has shown significant cytotoxic effects in NSCLC cell lines while showing 
only modest activity in non-cancerous cells, supporting the possibility that a therapeutic 
treatment window may be achievable. 
 In order to determine the effect on cellular levels of RPA, we prepared cell 
extracts from H460 cells treated for 8 hours with increasing concentrations of TDRL-505 
and analyzed the levels of RPA p34 and p70 using western blot analysis.  As shown in 
Figure 12B, the levels of the p70 and p34 subunits of RPA did not change following 
treatment with TDRL-505.  Indirect immunofluorescence was also used to determine the 
effect on RPA levels as well as its cellular distribution.  Using triton washing to 
dissociate proteins not tightly bound to DNA, we observed a decrease in the level of RPA 
staining following a 3 hour treatment with 50 µM TDRL-505, indicating a potential  
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Figure 10.  Effect of TDRL-505 on A549 NSCLC cells.  10A.  A549 cells were treated 
for 48 hours with increasing concentrations of TDRL-505 as indicated in the Figure.  
Cells were then analyzed for PI and Annexin V staining using flow cytometry.  PI and 
Annexin V staining are represented by the y- and x-axis, respectively.  10B.  
Quantification of 10A.  Duplicate samples were analyzed for Annexin V/PI staining 
following treatment with TDRL-505 and presented as the percentage of cells with no 
staining, indicative of live cells.  The IC50 of TDRL-505 in this treatment is ~38 µM. 
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Figure 11.  Effect of TDRL-505 on PBMCs.  11A.  PBMCs were harvested as 
described in section 2.2.11.  Cells were plated and treated with increasing concentrations 
of TDRL-505 as indicated for 24 hours.  Cells were then processed for Annexin V/PI 
staining using flow cytometry.  PI and Annexin V staining are represented by the y- and 
x-axis, respectively.  11B.  Quantification of the percentage of viable, untreated cells 
(Annexin V/PI negative) from duplicate samples.  The IC50 of TDRL-505 in PBMCs is 
estimated to be ≥ 100 µM.     
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decreased association of RPA with DNA following treatment with TDRL-505 without an 
overall decrease in protein level (Figure 12A).  This data coupled with the western blot 
analysis indicates that RPA is not being degraded by TDRL-505, but its association with 
DNA is decreased, which indicates a potential mechanism of action of TDRL-505 in 
H460 NSCLC cells. 
TDRL-505 prevents cellular entry into S-phase 
The impact of TDRL-505 on differential nuclear distribution of RPA and its 
induction of cytotoxcity indicates that inhibition of RPA binding to DNA is exerting an 
anti-proliferative effect that is being manifested by an inability of RPA to interact with 
the DNA.  RPA’s essential role in replication in a highly proliferative cell and its 
inhibition in this process would cause an inability to initiate DNA replication, leading to 
an accumulation of cells in the G1/S phase of the cell cycle and eventual cell death (100). 
Therefore we assessed the effect of TDRL-505 treatment on H460 cell cycle progression 
and observed an increase in the proportion of cells in the G1-phase of the cell cycle in 
response to treatment (Figure 13).  To determine if S-phase entry is inhibited in TDRL-
505 treated cells, cells were synchronized in G2/M with nocodazole and then released 
from G2 arrest and re-fed complete medium supplemented with either vehicle or 100 µM 
TDRL-505.  Both vehicle and TDRL-505 treated cells rapidly progressed through mitosis 
into G1 after removal of nocodazole (Figure 14A).  Cells that were treated with vehicle 
alone entered into G1, as seen at the 4 hour time point and progression into S-phase is 
apparent after 8 hours with progression into G2 evident at 12 hours (Figure 14A).  Cells 
that were treated with 100 µM TDRL-505 after release from nocodazole progressed into 
G1 but did not enter S-phase, even 12 hours post release.  Interestingly, when TDRL-505  
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Figure 12.  Cellular effect of TDRL-505 on RPA levels.  12A.  H460 cells were treated 
with 50 µM TDRL-505 or vehicle for 3 hours and analyzed for RPA expression and 
localization by indirect immunofluorescence using an Alexa Fluor594 secondary 
antibody (red).  Slides were counter stained with DAPI (blue) and images merged.  
Magnification of the boxed cells is presented below the lower magnification images. 12B. 
H460 cells were treated with increasing concentrations of TDRL-505 or vehicle for 8 
hours and RPA expression was assessed via western blot analysis probing for the p70 and 
p34 subunit as indicated.  Lane 2 is a vehicle treated control and Lanes 3-6 correspond to 
treatment with 25, 50, 75 and 100 µM TDRL-505, respectively. The positions of RPA 
p34 and p70 are indicated by the arrows.   
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Figure 13.  TDRL-505 induces a G1 arrest in H460 cells.  H460 cells were treated for 
48 hours with increasing concentrations of TDRL-505 as indicated.  DNA content was 
assessed using PI staining and analysis by flow cytometry.  The results presented are the 
average from 3 independent experiments. 
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was removed and cells were re-fed complete medium, they were able to reinitiate the cell 
cycle and proceed into S-phase (Figure 15).  However, cells that were re-fed with 100 
µM TDRL-505 showed prolonged G1 arrest and an increased sub-G1 population, 
typically indicative of cell death (Figure 15).  
To increase the resolution of the biochemical steps in the transition from G1 to S 
phase, we assessed BrdU incorporation using the same treatment protocol to analyze for 
cell cycle.  Following release of nocodazole arrested cells, 10 µM BrdU was added 2 
hours prior to collection and cells were analyzed by flow cytometry for BrdU 
incorporation.  In the presence of TDRL-505, no BrdU incorporation was observed while 
vehicle controls showed incorporation and progression through the cell cycle (Figure 
14A).  To determine the acute effect of TDRL-505 on DNA replication, asynchronous 
cells were treated with TDRL-505 for a short period of time (3 hours) and small but 
distinct differences in BrdU incorporation were observed (Figure 14B).  Cells treated 
with TDRL-505 appear to display a lengthening of S-phase and fewer cells that have 
incorporated BrdU progressing through the cell cycle into G2 (Figure 14B).  Therefore 
TDRL-505 influences the ability of H460 NSCLC cells to enter S-phase and induces a 
G1 arrest in these cells.   
TDRL-505 acts synergistically with cisplatin and etoposide in a NSCLC cell model 
 In addition to its essential role in DNA replication, RPA is involved in several 
DNA repair pathways including the repair of bulky DNA adducts as well as DNA breaks 
induced by various types of exogenous and endogenous agents.  The association of RPA 
with ssDNA is a significant feature of all of these pathways, indicating that inhibition of  
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Figure 14.  TDRL-505 prevents entry into S-phase. 14A.  H460 cells were treated with 
0.8 µg/mL nocodazole for 12 hours, washed then treated with either vehicle or 100 µM 
505 for 4, 8 and 12 hours. BrdU (10 µM) was added during the final 2 hours of treatment.  
Cells were then harvested and analyzed using flow cytometry for cell cycle distribution 
and BrdU incorporation. 14B. Asynchronous cells were treated for 3 hours with either 
vehicle or TDRL-505.  BrdU (10 µM) was added during the final hour of treatment and 
representative dot plots of the flow cytometry data are presented. 
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Figure 15.  Removal of TDRL-505 results in progression through the cell cycle.  
H460 cells were treated with 0.8 µg/mL nocodazole for 12 hours to induce a G2 arrest, as 
seen in Figure XA.  Following treatment, cells were washed and treated with 100 µM 
TDRL-505 for 12 hours after which cells were washed (vehicle) or compound was not 
removed (TDRL-505).  Cells were then grown for an additional 12 or 16 hours, as 
indicated.  Following the appropriate incubation period, cells were harvested and cell 
cycle distribution determined by PI staining and analysis with flow cytometry.  
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this activity would increase the cytotoxic effects induced by DNA damage.  In order to 
analyze the synergistic activity of TDRL-505 with DNA damaging agents, we measured 
the combination index (CI), a measure of the interaction of two cytotoxic agents.  We 
treated concurrently with increasing concentrations of cisplatin or etoposide along with 
increasing concentrations of TDRL-505.  Combination index analyses using the Chou-
Talalay method were performed with CI values greater than one indicative of an 
antagonistic effect, equal to one an additive effect, and less than one a synergistic effect 
(101).  H460 cells were treated independently with cisplatin, etoposide and TDRL-505 
and IC50 values were determined using Sigma Plot analysis (Figure 9B and Figure 16).  
TDRL-505 was determined to have an IC50 value of ~40 µM and cisplatin displayed an 
IC50 of ~4 µM (Figure 9A and Figure 16A, respectively).  The IC50 value of etoposide 
was determined to be ~0.15 µM (Figure 16B).  Using these values, cells were treated with 
increasing concentrations of total drug, maintaining a fixed ratio of the agents.  
AnnexinV/PI flow cytometry was conducted to examine the level of cell death and CI 
was calculated.   
 Cisplatin and TDRL-505 induced cell death individually however, when used in 
combination, cell viability was decreased to a level that was greater than that induced by 
either agent alone.  CI analyses were performed and revealed a synergistic effect between 
the two compounds with a CI of 0.4 at the highest fraction of cells affected (Figure 17).  
The interaction between the agents became additive and then antagonistic (revealed from 
CI values greater than one) at lower fractions of cells affected (Figure 17).  These results 
demonstrate that TDRL-505 is able to potentiate the effect of cisplatin in H460 cells and 
is consistent with inhibition of the cellular activity of RPA in NER.  
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Figure 16.  IC50 determination of Cisplatin and Etoposide in H460 cells.  16A.  H460 
cells were treated for 48 hours with increasing concentrations of cisplatin.  Following 
treatment, cells were harvested and stained with PI and Annexin V and analyzed by flow 
cytometry.  Quantification represents the average of 3 individual experiments and an IC50 
value of ~4 µM was estimated using Sigma Plot analysis.  16B.  H460 cells were treated 
with increasing concentrations of etoposide as indicated.  Samples were analyzed and 
quantified as described in 16A.  The IC50 value of etoposide was estimated to be 0.15 µM 
from Sigma Plot analysis.  
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Figure 17.  TDRL-505 acts synergistically with cisplatin and etoposide.  H460 cells 
were treated with increasing fractions of the IC50 concentration of either cisplatin or 
etoposide with TDRL-505 for 48 hours.  Following treatment, cells were harvested and 
analyzed for annexin V/PI staining using flow cytometry.  Open circles indicate CI 
analysis of cisplatin with TDRL-505 and closed circles represent etoposide with TDRL-
505.  The combination index analysis was performed as described in section 2.3.  The 
data are presented as the average ± SD from (N=3).   
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  RPA’s role in other DNA metabolic pathways led to us to examine the effect of 
TDRL-505 on cellular sensitivity to etoposide.  Etoposide induces replication fork arrest 
and is thought to lead to induction of strand breakage DNA damage responses, both 
cellular processes that require RPA (102).  Using the previously determined IC50 value of 
0.15 µM for etoposide and 40 µM for TDRL-505 in H460 cells, cells were treated with 
increasing concentrations of total drug, maintaining a fixed ratio of the agents.  
AnnexinV/PI flow cytometry was conducted to examine the level of cell death and CI 
was calculated.  Interestingly, TDRL-505 was found to have a synergistic effect with 
etoposide at all fractions of cells affected and suggests that TDRL-505 is able to inhibit 
the role of RPA in the repair of etoposide induced damage (Figure 17).   
 We sought to determine the mechanism of inhibition of TDRL-505 in the cellular 
response to etoposide by measuring the formation of RPA foci in response to etoposide in 
the presence and absence of TDRL-505.  Previous work has demonstrated that RPA 
forms distinct foci following etoposide treatment and plays a role in the cellular response 
to this treatment (103).  To analyze the effect on foci formation, we treated cells with 50 
µM TDRL-505 in the presence or absence of 25 µM etoposide for 4 hours and then 
processed cells to determine the level of RPA foci formation in response to etoposide.  
We did not observe a dramatic difference in the formation of etoposide induced RPA 
foci, however, small differences were observed between TDRL-505 and vehicle treated 
samples (Figure 18).  The overall total number of cells that showed RPA foci did not 
vary, however, the number of total foci formed in response to etoposide in the presence 
or absence of TDRL-505 did appear to be slightly different.  Further work will expand 
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Figure 18.  Indirect immunofluoresence of etoposide induced RPA foci.  H460 cells 
were treated with either vehicle or 50 µM TDRL-505 for four hours in the presence or 
absence of 25 µM etoposide as described in section 2.2.12.  Following incubation, cells 
were stained with anti-RPA p34 antibody (red) and DAPI (blue) and analyzed by 
microscopy as described in section 2.2.12. 
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our understanding of how TDRL-505 contributes to the cellular response to etoposide and 
the role of RPA in this response. 
2.4.  Discussion 
Since the discovery of RPA in the late 1980s, a great deal of mechanistic 
information has been gained concerning both its structure and ssDNA binding activity (3, 
104).  In addition, its participation in DNA replication and various DNA repair pathways 
has been effectively studied in reconstituted in vitro systems (28, 105-107).  Analysis of 
RPA function in genetic systems is complicated by the essential nature of the protein, 
stemming from the three subunits being encoded by separate genes (3).  Differences in 
solubility and expression of the three subunits has also presented problems of the analysis 
of truncation mutations and trying to analyze each subunit individually (3).  
Consequently, there has been somewhat limited analysis of RPA mutants in lower 
eukaryotes and other model systems in addition to limitations in the purification and 
analysis of mutants and individual subunits.  In an effort to develop reagents to probe the 
cellular activities of RPA, we undertook an in vitro high-throughput screen to identify 
SMIs of RPA’s DNA binding activity (92).  To date, the identification of inhibitors of 
DNA binding proteins has lagged behind analysis of inhibitors of the enzymatic activity 
associated with proteins, presumably due to a lack of a high-throughput protocol for 
analyzing DNA-binding activity.  However, considering the essential role DNA binding 
proteins play in the progression of cancer and its response to chemotherapy, targeting this 
activity has the potential for vast applications in cancer treatment (91).  
Inhibition of RPA’s DNA binding activity in a tumor cell line would be expected 
to have chemotherapeutic benefits due to RPA’s involvement in the essential process of 
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DNA replication (3).  Demonstration that TDRL-505 blocks cell entry into S-phase and 
results in a cytotoxic/cytostatic response in addition to decreased BrdU incorporation is 
consistent with inhibition of RPA’s role in DNA replication (100).  RPA is required both 
for assembly and firing of pre-replication complexes and elongation, in which it 
predominantly participates in lagging strand DNA synthesis (108).  RPA’s role in the 
early stages of DNA replication would predict a G1-arrest as cells are unable to progress 
into full DNA replication rather than an intra S-phase arrest, which we have observed.  
The potential exists that varying the concentration of TDRL-505 and time of treatment 
will alter the cell cycle distribution that we have observed.  While our data demonstrate a 
G1 block consistent with inhibiting the transition into S-phase, the potential that S-phase 
cells treated with TDRL-505 have reduced RPA binding and hence blocked elongation 
and firing of late replication forks cannot be ruled out.   
Our data reveals that cells are able to re-enter S-phase following removal of 
TDRL-505, suggesting that RPA inhibition is reversible or that newly synthesized RPA 
that is not bound to TDRL-505 is responsible for supporting re-entry into the cell cycle 
and leading to the initiation of DNA replication.  We have also demonstrated that RPA 
levels are not decreased following treatment with TDRL-505, however, the ability of 
RPA to associate tightly with DNA appears to be compromised.  This presents the 
possibility that the cytotoxic effects observed following treatment with TDRL-505 are 
due to inhibition of DNA replication, leading to toxicity in cells actively replicating their 
DNA, or that cells are unable to fully form replication foci, signaling for cell death.  
However, the continuation of G1 arrest may also induce cell death after prolonged 
periods of time, explaining why the degree of cell death after 48 hours of treatment is 
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greater than the number of cells that are in S-phase.  This allows for the possibility of a 
therapeutic window for specifically targeting actively dividing cells in the context of 
cancer treatment using SMIs to block the cellular activity of RPA.     
The role of RPA in DNA repair also allows for inhibition of its activity to 
increase the efficacy of chemotherapeutics that induce DNA damage, in the context of 
combination therapy.  Inhibition of DNA repair is anticipated to result in persistent DNA 
damage which is proposed to increase cytotoxicity.  We therefore examined the effect of 
RPA inhibition in an H460 NSCLC cell line in conjunction with cisplatin and etoposide 
treatment.  The indispensible role of RPA in the recognition and verification steps of 
NER is well characterized and, in addition, RPA participates in the re-synthesis step 
following excision of the damaged oligonucleotide (108).  Previous studies have shown 
that cells with decreased levels of NER proteins demonstrate increased sensitivity to 
cisplatin treatment (39).  Consistent with this, our data reveal a synergistic interaction 
between TDRL-505 and cisplatin at high fractions of cells affected, consistent with 
cellular inhibition of RPA and its role in NER.  Interestingly, at low fractions of cells 
affected, an antagonistic interaction is observed with combination indices greater than 
one.  This is likely the result of interactions not at the level of repair but at the level of 
signaling.  As cisplatin leads to activation of a G2 checkpoint and induces apoptosis from 
an extended G2 arrest, the finding that TDRL-505 blocks cells in G1 indicates that fewer 
cells would be subject to cisplatin induced G2 arrest.  Likewise, if TDRL-505 toxicity 
stems from an extended G1 arrest, the G2 checkpoint induced by cisplatin would result in 
less cell death as a result of treatment.  At high concentrations, this effect is mitigated by 
the interaction at the level of DNA repair with RPA inhibition increasing cisplatin 
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toxicity and overcoming the antagonistic signaling interaction.  The role of RPA in DNA 
replication restart and processing of collapsed replication forks also presents 
opportunities for combination therapy (109, 110).  Interestingly, combination index 
analysis of the activity of etoposide with TDRL-505 showed synergistic activity between 
the two agents at all fractions of cells affected.  Etoposide inhibits the enzymatic activity 
of topo II resulting in persistent covalent-cleavage complexes on DNA, which leads to 
replication fork arrest and both single- and double-strand DNA breaks (111).  RPA has 
been demonstrated to respond to and repair these types of lesions and DNA intermediates 
(102).  Therefore, inhibition of RPA would be expected to potentiate the effects seen by 
inhibiting topo II, which is observed in our analyses.  Secondly, due to the asynchronous 
nature of these cells, at any given time a cell undergoing replication would be expected to 
be in various stages of replication firing.  RPA is required in early replication firing and 
elongation, while topo II has been shown to be required for later stage replication events 
(112).  Therefore, inhibition of both stages of replication progression would be expected 
to show a greater effect than inhibiting either one of the steps individually, which would 
implicate a synergistic relationship between TDRL-505 and etoposide, which was shown 
using CI analysis.  The formation of RPA foci in response to etoposide was not 
significantly different in the presence or absence of TDRL-505.  One explanation may be 
that although RPA is accumulating into distinct foci in response to etoposide, the exact 
reason for this and the role that RPA plays in etoposide response is not known (102).  For 
instance, the overall level of direct RPA-DNA binding activity may be altered, but how 
this activity is involved in the cellular response to etoposide is not known.  The potential 
exists that RPA is unable to bind to DNA but interactions with other proteins contribute 
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to etoposide-induced foci formation, however the actual repair of these lesions does not 
occur as a result of decreased RPA-DNA binding.  The fact that increased cytotoxicity is 
observed with concurrent treatment of TDRL-505 and etoposide indicates that RPA 
inhibition does affect the cellular response to etoposide, however our lack of observation 
that decreased RPA foci form indicates that further tests examining concurrent vs. 
sequential treatment and variations in time and dose may tease out the mechanism of 
increased cellular sensitivity to etoposide treatment that we have observed. 
Considering the essential role of RPA in DNA metabolism, SMIs have the 
potential to elucidate the specific mechanistic roles of DNA binding activity and 
interaction with other proteins in each of the many DNA metabolic pathways in which 
RPA participates.  Examination of compounds that bind to particular domains within 
RPA has the potential to increase selectivity as well as allow the assignment of specific 
RPA-DNA interactions to specific pathways.  Although the primary role of RPA is as a 
ssDNA binding protein, it is unclear how this activity is coordinated to progression of 
DNA metabolic pathways.  For instance, previous studies have shown that mutation of up 
to five polar residues important for RPA-DNA interactions reduce ssDNA binding 
activity, but are able to complement the loss of RPA by siRNA knockdown (100).  
However, mutation of six polar amino acids leads to a cellular profile that is similar to 
that observed for knockdown of RPA (100).  This data indicates that the interaction with 
ssDNA may be lost to some extent and cellular function of RPA is still conserved.  
However, the effect of mutations on the level of binding compared to complete inhibition 
of RPA binding to DNA with a small molecule still leaves the question of the importance 
of RPA’s DNA binding activity on cellular function unanswered.  In addition, how 
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interactions with other proteins are altered following either residue mutation or binding to 
TDRL-505 is not known, but it is possible that a conformational change induced in 
mutating residues within RPA or by binding to TDRL-505 can lead to altered protein 
interactions. 
  Inhibition of RPA activity and abrogation of pathway function has the potential 
for widespread utility in cancer treatment.  While we focused on a subset of pathways, 
the role of RPA in several repair pathways opens up other opportunities for combination 
therapy.  Specifically, combining molecularly targeted RPA inhibition with radiation 
therapy could lead to increased cytotoxicity in tumor cells via inhibition of DNA DSB 
repair via non-homologous DNA end joining or homology directed repair, both of which 
have been shown to require RPA (107, 113, 114).  While targeting the enzymatic activity 
of proteins with small molecules is well accepted, the research presented here 
demonstrates the feasibility and utility of targeting a non-enzymatic protein-DNA 
interaction.  These compounds therefore represent the first SMIs of RPA which display 
both in vitro and cellular activity.  The approach of targeting RPA for cancer 
chemotherapy has several unique advantages including the lack of redundancy.  Unlike 
many signaling pathways, there are no back-up systems to counter act a loss of RPA 
activity.  While similar to oncogene signaling and the potential for oncogene addiction, 
RPA is essential for the continued proliferation of cancer cells and thus inhibition in 
rapidly dividing cancer cells provides a therapeutic window for treatment.  Additionally, 
the spectrum of cancers that would benefit from RPA inhibition is also significant as the 
reliance on RPA for increased cell proliferation and repair of chemotherapeutic DNA 
damaging agents is not unique to any single cancer.  Our targeting of the DNA binding 
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activity of RPA with a small, drug-like molecule sets the precedent for targeting this class 
of proteins and thus alters the current drug discovery paradigm to open up an entire new 
class of targets with potential broad spectrum utility. 
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3.  Determining the Mode of Inhibition of TDRL-505 
3.1.  Introduction 
 Inhibition of RPA’s DNA binding activity by TDRL-505 is suggestive of an 
interaction between TDRL-505 and the main ssDNA binding domains (DBD-A and -B) 
found within p70.  This is evidenced by inhibition of RPA’s DNA binding activity on a 
short 12 base substrate as shown in Figure 8C in which binding is largely restricted to 
DBDs-A and -B (AB region).  In order to further define the interaction between TDRL-
505 and RPA, we used in silico docking to predict where TDRL-505 interacts within the 
p70 domain of RPA.  We purified the AB region of RPA p70 as well as a mutant 
heterotrimeric form of RPA, both of which were found to be inhibited by TDRL-505.  
Interestingly, we observed no inhibition of WT heterotrimeric RPA, mutant 
heterotrimeric RPA, or the AB region of p70 by TDRL-505 on dsDNA containing a 1,2 
(dGpG) cisplatin lesion. 
 The ability of RPA to interact with many proteins found in DNA metabolic 
processes suggests that its role extends beyond that of a single-strand DNA binding 
protein and may play a larger role in signaling and ensuring maintenance of the genomic 
sequence.  The potential of SMIs of RPA to further elucidate these actions by blocking 
protein-protein interactions due to either direct or indirect inhibition has the potential to 
provide novel biochemical information on the cellular function of RPA.  Also, the ability 
of SMIs to inhibit RPA’s role in a pathway specific manner has implications both in a 
chemotherapeutic context as well as in delineating the biological role of RPA in various 
DNA metabolic pathways. 
  
79 
 
3.2.  Materials and Methods 
3.2.1.  Materials 
 DNA substrates were obtained from IDT (Coralville, IA) and prepared as 
described in 2.2.3.  Sequences can be found in Appendix A.  Wildtype RPA p11 plasmid 
and mutant W361A p11 plasmid were obtained from Dr. Marc Wold from the University 
of Iowa.  Klenow fragment (5′-3′exo-, 3′-5′exo-, 5,000 units/mL) was obtained from New 
England Biolabs.  Phosphocellulose matrix was obtained from Sigma.  Goat α-XPA 
primary antibody was obtained from Santa Cruz Biotechnology and goat α-rabbit 
secondary antibody was obtained from Biorad.     
3.2.2.  In Silico Docking 
 In silico docking of TDRL-505 with the central DNA binding domain of RPA p70 
(1FGU) was performed using Autodock 4.2 (115).  Three independent grids were 
established 60Å in each dimension to encompass either the interdomain region, DBD-A 
or DBD-B.  Semi-flexible automated ligand docking was performed using the Monte 
Carlo based simulated annealing and locality search algorithms.  The most stable 
complexes were selected based on binding energies from multiple analyses.  Coordinates 
of the final docked complexes were displayed with PyMOL (DeLano Scientific, LLC).  
Docking analysis was performed by John Turchi (Indiana University School of 
Medicine). 
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3.2.3.  Purification of the AB region of RPA 
 The AB region of RPA p70 was prepared by transforming BL21 competent 
bacterial cells with pET15b-AB plasmid DNA.  The cells were induced with IPTG and 
incubated at 37°C for two hours.  Following induction, cells were harvested by 
centrifugation at 700 x g for 30 minutes at 4°C.  The pellet was resuspended in buffer A 
(20 mM Tris, pH 7.5, 10% glycerol, 500 mM NaCl, 10 mM β-mercaptoethanol (BME) 
and 1 µg/mL PMSF, leupeptin and pepstatin).  Cells were resuspended in 1 mL/gram of 
cells, sonicated and pelleted at 15,000 x g for 30 minutes at 4°C.  The supernatant was 
then loaded onto a 10 mL phosphocellulose column and the flow through collected.  
Imidazole was added to 5 mM to the flow through which was then loaded onto a 2 mL 
nickel column at 0.5 mL/minute.  The column was then washed with buffer A containing 
50 mM imidazole after which protein was eluted from the column using a gradient from 
50-500 mM imidazole.  Fractions were analyzed for protein content using Bradford and 
SDS-Page analysis in addition to assessment of DNA binding activity as determined by 
anisotropy.  Fractions were pooled based on those which contained the AB region and 
dialyzed overnight in buffer B (1 mM Hepes, pH 7.2, 10 mM DTT, 50 mM NaCl and 1 
µg/mL PMSF, pepstatin and aprotinin).  Aliquots were then stored at -80°C.  
(Purifications were performed by Sarah Shuck and Victor Anciano, Indiana University 
School of Medicine). 
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  3.2.4.  XPA Purification 
 [His]6 -XPA was expressed by infecting 200 mL of Sf9 cells with recombinant 
human XPA virus at a multiplicity of infection of 10.  After 48 hour infection, cells were 
sedimented at 4,000 x g for 5 minutes at 4°C.  Cells were then lysed by dounce 
homogenization in 30 mL of lysis buffer containing 50 mM Tris, 100 mM NaCl, 0.1% 
Triton X-100, 10% glycerol, 10 mM BME and 1µg/ml PMSF, pepstatin, leupeptin and 
aprotinin.  The extract was then sonicated at 5 x 0.1s and the lysate was sedimented at 
7800 x g at 4°C for 15 minutes.  Imidazole was added to 1 mM to the supernatant and 
was loaded onto a 2 mL nickel-NTA agarose column at the rate of 1 mL/min.  The 
column was then washed with nickel buffer (50 mM Tris, pH 8, 100 mM NaCl, 0.01% 
Triton X-100, 10% glycerol, 10 mM BME, 0.5 mM ZnCl2, 1 mM imidazole and 1 µg/mL 
PMSF, aprotinin and pepstatin).  The protein was then eluted with 20 mL of nickel buffer 
containing 80 mM imidazole into 1 mL fractions and protein containing fractions were 
identified by Bradford analysis.  Fractions containing more than 50% of the total protein 
were pooled and applied to a 2 mL heparin-sepharose column and washed with heparin 
buffer (50 mM Tris, pH 7.5, 1 mM EDTA, 10% glycerol, 100 mM NaCl, 1 mM DTT and 
1 µg/mL pepstatin, aprotinin and PMSF).  Following column washing, protein was eluted 
using a gradient from 0.1 M to 1M NaCl.  Protein containing fractions were identified by 
Bradford analysis and XPA containing fractions were identified by SDS-PAGE analysis.  
XPA containing fractions were pooled and dialyzed overnight in heparin buffer and 
stored at -80°C. 
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3.2.5.  EMSA Analysis of AB Region of RPA p70 
 Purified AB region was analyzed for DNA binding activity to a 34-base purine 
rich ssDNA substrate (SJC 1.5 Xba).  Protein was titrated from 1-100 pmol and incubated 
with 500 fmol of 5′[32P] labeled 34-base DNA for 5 minutes at room temperature in a 
final reaction volume of 30 µL.  Reactions were then loaded onto a 6% native 
polyacrylamide gel and electrophoresed at 170 volts for 1 hour.  Gels were then dried and 
exposed to a PhosphoImager screen (Molecular Dynamics) for 30 minutes.  The screen 
was then scanned using a Storm 820 (Amersham Biosciences) and quantified using 
ImageQuant software (Molecular Dynamics).  It was determined that 50% of protein was 
bound at 10 pmol total protein.  To determine the effect of TDRL-505 on AB region-
DNA interactions, 10 pmol of protein was incubated for 5 minutes with either 1% DMSO 
or increasing concentrations of TDRL-505 as indicated in the Figure legend.  TDRL-505 
was diluted from a 10 mM stock into a 0.5 mM dilution in 10% DMSO and 10 µM 
Hepes, pH 8.0.  The reactions were then mixed with 500 fmol of DNA in a final reaction 
volume of 30µL and incubated for five minutes at room temperature.  Samples were then 
electrophoresed and analyzed as described above.  The results indicate the average and 
standard deviation from at least 3 individual experiments.  The IC50 values were 
calculated using Sigma Plot analysis.  
3.2.6.  Preparation of 1,2 cisplatin damaged DNA 
 SCS 1.1 and 1.2 substrates (40-nt and 41-nt, respectively) were gel purified as 
described in section 2.2.3.  Sequences may be found in Appendix A.  Following gel 
purification, 1 nmol of SCS 1.1 ssDNA was platinated at a final concentration of 1 
pmol/µL DNA with 10 nmol of cisplatin overnight at 37°C in the dark.  The 1,2 dGpG 
83 
 
cisplatin damaged DNA was ethanol precipitated with 3:1 volume ratio of 100% EtOH at 
-20°C:DNA, 0.3 M NaAc, and 20 µg/mL glycogen for 1 hour at -80°C.  The DNA was 
then sedimented at 10,000 x g for 45 minutes at 4°C and then resuspended in 20 µL dH2O 
and concentration determined by absorbance reading at 260 nm.  The 1,2 Pt SCS 1.1 
substrate was then annealed to SCS 1.2 at a ratio of 1.5:1 in a 20 µL reaction containing 
50 mM Tris, pH 7.5, 10 mM MgAc, and 5 mM DTT with heating at 95°C for 5 minutes 
followed by cooling to room temperature for 1 hour.  SCS 1.1 was then extended by 1 
nucleotide (dCTP) in an extension reaction containing 10 mM Tris-HCl, 50 mM NaCl, 10 
mM MgCl2, and 1 mM DTT, pH 7.9 with 5 units of Klenow fragment and 0.45 µM of 
α[32P]dCTP by incubating at 37°C for 30 minutes.  Following incubation, 200 µM non-
radioactive dCTP was added to the reaction and incubated for 5 minutes at 37°C.  20 mM 
EDTA was then added to the reaction and dH2O was added to bring the final volume to 
50 µL.  The concentration of the DNA was then determined using scintillation counting. 
3.2.7.  EMSA analysis of W361A and WT RPA binding to DNA 
 W361A mutant heterotrimer RPA was purified as described in section 2.2.4. 
(Victor Anciano) and analyzed for DNA binding activity.  Increasing concentrations of 
both WT and W361A RPA (as indicated in the Figure legend) were incubated with 500 
fmol of SJC 1.5 Xba (Appendix A) 34-base DNA for five minutes at room temperature in 
35 µL reactions containing 1x agarose dye (see section 2.2.6).  Following incubation, 
reactions were loaded onto a 6% non-denaturing polyacrylamide gel and electrophoresed 
at 170 volts for 1 hour.  Gels were then dried and exposed to a PhosphoImager screen 
(Molecular Dynamics) for 30 minutes.  The screen was then scanned using a Storm 820 
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(Amersham Biosciences) and quantified using ImageQuant software (Molecular 
Dynamics).   
3.2.8.  EMSA analysis of WT and W361A RPA with TDRL-505  
 Increasing concentrations of TDRL-505 were incubated with 125 nM WT RPA or 
250 nM W361A mutant RPA for five minutes at room temperature as described in 
section 2.2.6.  Following incubation, 12.5 nM 1,2 Pt damaged SCS 1.1/1.2 dsDNA was 
added to the reactions which were incubated an additional five minutes at room 
temperature.  Samples were then processed and analyzed as described in section 2.2.6.  
The results indicate the average and standard deviation from at least 3 individual 
experiments. 
3.2.9.  ELISA Analysis of RPA-XPA interactions 
 To determine the effect of TDRL-505 on RPA-XPA interactions, 200 ng of 
purified XPA (section 3.2.4) was incubated with 100 µL of PBS overnight in a 96-well 
ELISA plate at 4°C.  Following XPA binding, wells were washed 3 x 5 minutes with 200 
µL PBS.  200 µL of blocking buffer (PBS + 2% BSA) was added to each well for 2 hours 
at room temperature with rocking.  Following blocking, 300 ng of RPA was pre-
incubated with increasing concentrations of TDRL-505 in blocking buffer containing 3% 
DMSO in 100 µL reactions for 10 minutes at room temperature, following which 50 µL 
was added to each well, in duplicate, for 1 hour with rocking.  Following incubation, 
wells were washed 3 x 5 minutes with 200 µL blocking buffer after which 50 µL mouse 
anti-RPA p34 antibody (Neomarkers) (1:500 in blocking buffer) was added to each well 
for 1 hour with rocking.  Wells were then washed 3 x 5 minutes with 200 µL blocking 
buffer after which 50 µL of goat anti-mouse secondary antibody (Santa Cruz 
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Biotechnology) (1:2500 in blocking buffer) was added to each well for one hour with 
rocking.  Following the final wash, 100 µL of TMB-ELISA reagent (Thermo Scientific) 
was added to each well and kinetic analysis was performed with readings at wavelengths 
370 and 490 nm at 30 second intervals for 20 minutes on a SpectraMax M5 (Molecular 
Devices, Silicon Valley, CA).  The results indicate the average and standard deviation 
from at least 3 individual experiments.     
3.2.10.  ELISA Analysis of XPA-DNA interactions with TDRL-505 
 ELISAs were performed by binding 200 fmol per well of biotinylated 60-nt 
single-strand DNA in blocking buffer (2% BSA TBS-Tween) overnight on strepavadin 
coated plates (Roche Applied Science).  Inhibition of protein binding was examined by 
incubating 10 ng of purified XPA with increasing concentrations of TDRL-505 as 
indicated in 150 µL reactions containing 5% DMSO and blocking buffer for 10 minutes 
at room temperature.  Following incubation, 100 µL of the reaction was added to each 
well, in duplicate, and incubated for 1 hour with rocking.  The amount of protein bound 
to DNA was analyzed by incubating 50 µL of goat anti-XPA antibody (Santa Cruz 
Biotechnology) (1:1000 in blocking buffer) in each well for 30 minutes with rocking.  
Following incubation with primary antibody, wells were washed 3 x 5 minutes with 200 
µL of blocking buffer followed by the addition of 50 µL of goat anti-rabbit secondary 
antibody (Biorad) (1:2500 in blocking buffer) for 30 minutes.  Wells were then washed as 
described above and 100 µL of TMB-ELISA reagent (Thermo Scientific) was added to 
each well.  Kinetic reads were performed using a SpectraMax M5 spectrophotometer 
(Molecular Devices, Silicon Valley, CA) for 20 minutes at 30 second intervals at 370 and 
86 
 
490 nm wavelengths.  The results indicate the average and standard deviation from at 
least 3 individual experiments.   
3.3.  Results 
Molecular Modeling of AB Domain of RPA p70 
We undertook a molecular modeling approach to determine if the OB-folds of 
RPA p70 were the potential target of TDRL-505.  The crystal structure of RPA p70 181-
422 was previously solved in the absence of DNA by Bochkareva et al. (116) and 3-
dimensional data obtained from the protein data bank (1FGU).  TDRL-505 was prepared 
as the ligand using Autodock tools 1.5.2 as described in section 3.2.2.  A semi-flexible 
approach was employed maintaining RPA in a rigid conformation and allowing 
flexibility of the ligand.  Docking was performed using Autodock 4.2 with random initial 
positioning of the ligand and three potential binding sites were identified based on the 
lowest interaction energies.  These sites include each of the OB-folds (DBD-A and -B) 
and the interdomain region between the two folds (Figure 19).  The most stable 
interaction was with DBD-B and the conformation of TDRL-505 within this site is 
depicted in green.  DBD-A domain (TDRL-505 in blue) ranked second in binding energy 
and lastly the interdomain region (TDRL-505 in red).  The close-up of the interaction 
presented in the insets reveal that most of the stability is driven via hydrophobic 
interactions, although the conserved oxo-butyric acid is stabilized via interactions with 
basic amino acids in each of the three positions.  To determine the relative importance of 
the interaction of TDRL-505 with each domain, docking analysis of TDRL-518 was 
performed.  TDRL-518 shows no inhibition of RPA’s DNA binding activity in vitro and 
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Figure 19.  Docking analysis of TDRL-505 in the AB region of RPA.  Surface 
representation of RPA p70 181-422 (1FGU) with TDRL-505 docked in DBD-A (blue), 
DBA B (green) and the interdomain region (red).  Each insert is a close up of the 
interaction of each respective domain with TDRL-505 as modeled to give the lowest 
activation energy. 
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dramatic alterations in binding energies were obtained.  Significantly increased ∆G 
values were obtained for interactions with DBD-B and the interdomain region while only 
modest increases were calculated for the interaction with DBD-A.  These data suggest 
that the majority of the inhibitory effect of TDRL-505 is manifested through interaction 
with the DBD-B OB-fold. 
TDRL-505 inhibits RPA AB region interactions with DNA 
Molecular modeling analysis revealed a thermodynamically favorable interaction 
between TDRL-505 and regions in the AB domain and we wished to determine the effect 
of TDRL-505 on the in vitro DNA binding activity of the AB region of RPA.  This region 
extends from amino acids 181-432 and has been purified and analyzed for DNA binding 
activity and displays approximately 1/25 activity compared to WT RPA (117).  A subset 
of this region from amino acids 181-422 was crystallized in complex with a (dC)8 DNA 
substrate and the structure solved in addition to a DNA-free structure with the entire 181-
432 amino acid region (54, 116).  In order to examine the effect of TDRL-505 on the AB 
region alone, we cloned the region of RPA from amino acids 181-432 in the p70 subunit 
of RPA and expressed it in a pET15b plasmid expression system (Jennifer Earley, 
Indiana University School of Medicine).  The AB region was purified from BL21 E. coli 
cells and analyzed for DNA binding activity (Figure 20A) (Victor Anciano and Sarah 
Shuck).  EMSA analysis revealed binding to a 34-base substrate with 50% of protein 
bound at 5 pmol total protein (Figure 20B).  Examination of TDRL-505 on inhibiting the 
AB region from binding to DNA revealed a concentration dependent decrease in AB 
binding with an IC50 of 40 µM (Figure 21). 
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Figure 20.  AB region of RPA binding to DNA.  20A.  The AB region of RPA was 
cloned and purified as described in section 3.2.3.  Lane 1-Low molecular weight marker, 
2-Whole cell extract, 3-Nickel column, flow through, 4-Nickel column, wash, 5-9-Nickel 
column fractions.  20B.  EMSA analysis of the AB region binding to SJC 1.5 Xba 
dsDNA (Appendix A).  Increasing amounts of the AB region were incubated with 500 
fmol of DNA and electrophoresed as described in section 3.2.5.  The percentage of 
protein bound relative to the total pmol of protein in each reaction was quantified and 
displayed in 20C.   
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Figure 21.  Inhibition of AB region binding to DNA by TDRL-505.  21A.  10 pmol of 
the AB region was pre-incubated with increasing concentrations of TDRL-505 as 
described in section 3.2.5.  500 fmol of SJC 1.5 Xba ssDNA (Appendix A) was then 
added to each reaction and electrophoresed on a native polyacrylamide gel.  21B.  
Quantification of 21A.  The data represent quantification and standard deviation of 4 
independent experiments.   
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Identification of residues potentially important for TDRL-505 interaction with RPA 
 In order to further discern the mode of interaction between RPA and TDRL-505, 
we examined the potential sites of interaction between TDRL-505 and the AB region of 
RPA.  We chose to examine amino acids found within DBD-B and the interdomain 
region that are in close proximity for interaction with TDRL-505 based on the in silico 
docking studies.  We examined RPA in the open conformation, as is seen in Figure 4A.  
Modeling of TDRL-505 is shown in Figure 22 and two residues, W361 and K273 were 
identified from DBD-B and the interdomain region, respectively, as potential sites of 
interaction with TDRL-505.  Previous work from Dr. Marc Wold’s laboratory has 
identified a W361A mutation that has reduced DNA binding activity, indicating its 
importance in DNA interactions (118).  In order to measure the effect of a residue on 
TDRL-505 activity, RPA’s DNA binding activity must be retained, making W361A an 
attractive mutation to study due to its preservation, albeit reduced DNA binding activity.  
In addition to the close proximity between W361 and TDRL-505, this residue is found 
within the DNA binding domain, which we think is the mode of contact of TDRL-505.  
In order to measure the contribution of W361 on stabilizing TDRL-505, we obtained the 
full length RPA p11 plasmid containing the W361A mutation from Dr. Marc Wold 
(University of Iowa) and purified this protein (Figure 23A, Victor Anciano).  We 
observed approximately a 20% decrease in W361A RPA binding compared to WT RPA 
when examining binding to SJC 1.5 Xba (sequence in Appendix A), consistent with 
previous data (118).  However, no difference in inhibition by TDRL-505 was observed, 
indicating that this residue is not required for the stable binding of TDRL-505 (data not 
shown).  Because TDRL-505 was modeled with RPA in the open conformation, the  
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Figure 22.  Modeling of TDRL-505 in AB Region. The crystal structure of RPA p70 
from residues 181-422 was analyzed using PYMOL analysis of the PBD file 1FGU.  
TDRL-505 was modeled against DBD-B and the interdomain region.  Close up of each 
region is represented with the DBD-B region on the left panel and the interdomain region 
on the right.  W361 and K273 are displayed as indicated. 
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Figure 23.  Purification and characterization of RPA W361A mutant.  23A.  Mutant 
W361A RPA was expressed and purified as described in section 2.2.4.  Purified protein 
was analyzed by SDS-Page analysis and was stained with coomassie blue.  Lane 1-Low 
molecular weight marker, 2-W361A, pool A, 3-W361A, pool B.  23B.  EMSA analysis of 
W361A and WT RPA binding to 34-base ssDNA (SJC 1.5 Xba).  Lanes 1 and 7 indicate 
DNA with no RPA.  Lanes 2-6 and 8-12 indicate 0.5, 1, 2.5, 5 and 10 pmol of total 
protein.    
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potential exists that TDRL-505 interacts with RPA and induces a conformational change 
that is similar to that seen with DNA.  Therefore, W361 may not be within proximity to 
interact with TDRL-505 if the conformation of this protein is dramatically altered 
following binding of TDRL-505.   
TDRL-505 does not inhibit RPA binding to 1,2 cisplatin damaged DNA 
 Previous work has shown that RPA has a preference to bind to cisplatin damaged 
DNA compared to undamaged duplex (60).  It was hypothesized that this increase in 
binding activity is due to RPA recognizing the single-strand DNA character that is 
introduced in the duplex by the cisplatin adduct (60).  However, which OB-folds are 
important for this binding activity has not been elucidated.  After determining that the 
mode of interaction between TDRL-505 and RPA appears to be within the AB region of 
RPA, we examined the ability of TDRL-505 to inhibit RPA binding to 1,2 Pt damaged 
dsDNA (SCS 1.1/1.2, sequences in Appendix  A) to determine the contribution of the AB 
region to binding this type of lesion.  We did not observe any significant inhibition of 
binding with TDRL-505 when tested at 50 µM, indicating the area in which TDRL-505 
interacts with RPA is not important for RPA’s interaction with 1,2 Pt dsDNA (Figure 24).  
We also examined the ability of W361A RPA to bind to 1,2 Pt dsDNA to determine its 
contribution to binding to 1,2 Pt damaged DNA.  We observed binding by W361A at half 
the maximum level of binding for WT RPA, which is similar to that seen for binding to 
ssDNA (Figure 24A).  This result indicates that W361 is not required for interaction with 
1,2 Pt damaged 41-nt DNA, although it may contribute to binding to some extent.  The 
ability of TDRL-505 to inhibit binding of W361A RPA to 1,2 Pt damaged DNA was also 
analyzed and no inhibition of binding was observed, similar to the results obtained for  
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Figure 24.  TDRL-505 does not inhibit RPA binding to 1,2 cisplatin damaged DNA.  
24A.  WT or W361 mutant RPA was pre-incubated with increasing concentrations of 
TDRL-505 as indicated in 24B.  Following pre-incubation, 500 fmol of 1,2 Pt damaged 
dsDNA was added to each reaction and incubated for an additional 5 minutes.  Samples 
were then electrophoresed on 6% native polyacrylamide gels and analyzed as described 
in section 3.2.8.  24B.  The percentage of RPA bound compared to RPA control was 
calculated and the average and standard deviation from 3 independent experiments are 
presented.   
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Figure 25.  EMSA analysis of the AB region of RPA binding to 1,2 Pt dsDNA.  25A.  
Increasing concentrations of TDRL-505 were incubated with purified AB region of RPA 
as described in section 3.2.5.  Following incubation, 500 fmol of SJC 1.5 Xba DNA was 
added to each reaction after which they were electrophoresed on a 6% native gel and 
visualized as described in section 3.2.5.  25B.  Quantification of 26A, the results 
represent the average and standard deviation from at least 3 independent experiments. 
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WT RPA (Figure 24).  Binding to 1,2 Pt dsDNA by the AB region of RPA was also 
examined.  A significant amount of protein (500 pmol compared to 5 pmol of WT RPA) 
was required to see ~40% of protein binding but an interaction between the AB region 
and 1,2 Pt dsDNA was observed.  Analysis of this interaction in the presence of TDRL-
505 revealed no inhibitory activity on this substrate (Figure 25). 
TDRL-505 inhibits the XPA-RPA interaction 
 Previous studies have shown that RPA interacts with XPA through the p34 and 
p70 subunits (119).  In order to determine if TDRL-505 affects the interaction between 
RPA and XPA and to further define the mode of interaction between TDRL-505 and 
RPA, we employed ELISA analysis to examine the RPA-XPA interaction.  XPA (10 ng) 
was bound to an ELISA plate overnight following which 300 ng of RPA pre-incubated 
with increasing concentrations of TDRL-505 were added to each well containing XPA.  
Antibody against RPA was then added to each well and the amount of RPA that was 
bound to XPA was determined.  As shown in Figure 26A, the interaction between RPA 
and XPA is inhibited, albeit with a fairly high concentration of TDRL-505.  
Immunoprecipitation experiments were performed in order to ascertain if TDRL-505 
inhibits the interaction between the p34 antibody and the p34 subunit (data not shown).  
These experiments indicate that TDRL-505 does not inhibit this interaction, indicating 
that the observed loss of RPA-XPA binding is due to inhibition of the interaction between 
the two proteins and is not a result of decreased detection.   
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Figure 26.  TDRL-505 inhibits the interaction between RPA and XPA but does not 
inhibit XPA binding to DNA.  26A.  XPA was bound to ELISA plates as described in 
section 3.2.9.  Increasing concentrations of TDRL-505 were pre-incubated with RPA and 
then added in duplicate to the ELISA plate.  The ELISA assay was performed as 
described in section 3.2.9.  The graph represents the average and standard deviation of 4 
independent experiments.  26B.  XPA binding to 60-nt ssDNA was assessed using 
ELISA analysis as described in section 3.2.10.  Increasing concentrations of TDRL-505 
were pre-incubated with 10 ng of XPA and then added in duplicate to the ELISA plate.  
The assay was performed as described in section 3.2.10.  The graph represents the 
average and standard deviation of 5 independent experiments.     
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TDRL-505 does not inhibit the XPA-DNA interaction 
 In order to determine the specificity of TDRL-505 for RPA, we measured the 
ability of the compound to inhibit XPA’s DNA binding activity.  Although RPA and 
XPA interact with DNA differently, they both participate in an early step of nucleotide 
excision repair and are thought to be important for recognizing damaged DNA.  XPA 
shows varying degrees of DNA binding activity when examined using EMSA analysis, 
prompting us to employ a different method to measure this activity.  We therefore used 
ELISA analysis to measure XPA binding to TMN 1.1 biotinylated 60-nt DNA.  TDRL-
505 was titrated up to 50 µM as shown in Figure 26B, however no inhibition of XPA 
binding was observed, indicating some degree of specificity of TDRL-505 for RPA.  
Analysis of inhibition on an OB-fold containing protein such as Pot1 might give further 
indication of the specificity of TDRL-505 for RPA.    
3.4.  Discussion 
Considering the complexity of the RPA structure, which is comprised of six OB-
folds distributed throughout three subunits, targeting DNA binding activity using a SMI 
has the potential to elucidate the contribution of these various regions to the numerous 
activities of RPA in DNA replication, repair and recombination.  Targeting a particular 
OB-fold may allow for pathway-specific targeting of RPA.  For instance, one could 
inhibit RPA’s activity in NER and not in replication which would present clinical utility 
in cancer treatment to allow synergy with other agents while limiting potential toxicity.  
It has been suggested the OB-folds beyond DBD-A and -B contribute to RPA’s 
interaction with different DNA substrates stemming from the observation that DBD-A 
and -B can accommodate a (dC)8 DNA substrate, however variations in binding constants 
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are observed on sequences of various length, indicating a role for additional OB-folds in 
the RPA-DNA interaction (3).  Our observation that TDRL-505 can specifically inhibit 
the AB region of p70 from binding to DNA supports the molecular modeling data in 
which energetically favorable binding was observed within DBD-A and -B as well as the 
interdomain region. 
TDRL-505 does not inhibit RPA-DNA interactions when examining a 1,2 dGpG 
cisplatin lesion on a 41-nt dsDNA susbstrate (SCS 1.1/1.2).  Previous data has shown that 
the binding of RPA to this type of substrate is a result of RPA binding to and separating 
duplex DNA and the observed gel shift is the result of RPA bound to undamaged ssDNA 
(120).  Our observations indicate that the mode of interaction between RPA and 1,2 Pt 
damaged dsDNA is not inhibited by TDRL-505.  Attempts to measure the strand 
separation activity of RPA on this substrate have not indicated clear strand separation, 
however additional work may further define this activity (data not shown).  Our results 
indicate that mode of interaction between heterotrimeric WT RPA is different when 
comparing ssDNA to 1,2 Pt damaged DNA.  The potential exists that TDRL-505 binding 
to RPA prevents the AB region from interacting with 1,2 Pt damaged DNA and therefore 
other regions of RPA are important for this interaction.  It is also possible that the initial 
binding step to this substrate does not require the AB region, however it is required to 
form a stable complex.  For instance, if TDRL-505 is transiently binding to RPA, initial 
binding by another region could bring the AB region into close proximity to the substrate 
and if TDRL-505 becomes unbound, the AB region is then free to interact with DNA.  
This is not observed for ssDNA substrates because the AB region is the main domain 
responsible for ssDNA interactions and TDRL-505 may never become unbound long 
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enough to permit this interaction.  It is also possible that the AB region is not required for 
binding to this substrate but is required for processing of the cisplatin adducts and/or 
strand separation activity.  Further experiments to determine the effect of TDRL-505 on 
the binding of other NER proteins and the processing of Pt lesions will result in a clearer 
understanding of how RPA’s ssDNA binding activity is required in DNA metabolic 
processes.   
The fact that no inhibition of the AB region binding to 1,2 Pt dsDNA was 
observed indicates that this region is sufficient for binding to this substrate.  Previous 
work has identified that RPA binding is correlated to ssDNA that is produced as a result 
of its strand separation activity (120).  We are currently working to elucidate if the AB 
region has DNA unwinding activity and if this correlates with DNA binding activity that 
we observe.  Observation that TDRL-505 does not inhibit AB region binding to 1,2 Pt 
DNA indicates that this region is interacting with this DNA substrate differently than that 
observed for ssDNA and that TDRL-505 does not block this interaction.  Because only a 
short DNA sequence was modeled in the crystal structure of the AB region, it is unclear 
how this region is interacting with a longer, cisplatin damaged substrate.  Also, the large 
amount of protein it takes to bind ~40% this substrate compared to ssDNA (500 pmol vs. 
10 pmol) indicates that the mode of interaction is different, either in the sense of 
decreased strand separation activity of if there is no strand separation activity, a decrease 
in the amount of binding to the damaged substrate.  The potential also exists in which the 
on and off rates of the AB region for 1,2 Pt DNA are such that detection of inhibition of 
binding is not possible using EMSA analysis. 
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Further analysis examining the effect of TDRL-505 in preventing the XPA-RPA 
interaction determined that this interaction is prevented at high concentrations, without 
affecting the ability of XPA to bind to ssDNA.  The interaction domain between RPA and 
XPA is primarily thought to be located within the p34 subunit of RPA, but there is some 
evidence that p70 can interact as well, although perhaps to a lower extent (119, 121).  
Therefore, inhibition of the XPA-RPA interaction with TDRL-505 supports targeting of 
DBD-A and -B, and decreasing the ability of these two subunits to interact.  It is unclear 
if this inhibition is due to direct steric hindrance of TDRL-505 in preventing the XPA-
RPA interaction, or if binding of DBD-A and -B to TDRL-505 somehow induces a 
conformational change that prevents the XPA-RPA interaction.  It would be interesting to 
examine the affect of TDRL-505 on RPA’s influence on XPA’s DNA binding activity.  It 
is unclear at this point if RPA is required to bind to DNA in order to interact with XPA 
and/or recruit it to sites of damage.  To determine the specificity of TDRL-505 for RPA, 
we examined its ability to inhibit XPA’s DNA binding activity.  We did not observe any 
decrease in XPA binding to ssDNA up to 50 µM of TDRL-505, providing evidence that 
inhibition of the RPA-XPA interaction is due to specific binding of TDRL-505 to RPA.  
By targeting DBD-A and -B, we have shown inhibition of RPA’s ssDNA binding activity 
but not inhibition of binding to 1,2 Pt dsDNA, implicating other OB folds in this 
interaction.  Current work is being conducted to crystallize the AB region with TDRL-
505 to further determine the sites of interaction.  We are also currently working on 
making additional mutations within RPA to elucidate which residues are important for 
the interaction between RPA and TDRL-505.  The ability to specifically target particular 
OB-folds within RPA presents the possibility that SMIs can be designed to inhibit 
103 
 
pathway specific roles of RPA, allowing for this protein to be targeted within individual 
repair pathways and/or within replication.  This has the potential to further elucidate the 
role of RPA within DNA repair pathways and replication and also presents the possibility 
of targeting RPA’s role in a specific pathway in a clinical setting.  This inhibition can be 
coupled with chemotherapeutic treatments and may minimize toxic side effects that 
might occur from solely inhibiting DNA replication. 
  
104 
 
4.  Small Molecule Inhibition of Xeroderma Pigmentosum Group A 
4.1.  Introduction 
 Mutations in XPA account for 90% of the observed phenotype in XP, highlighting 
the essential nature of this protein for efficient NER (9). In addition to its role in cancer 
development, XPA has been implicated in chemotherapeutic response to cisplatin 
treatment (39).  As discussed previously, sensitivity to cisplatin treatment has been 
correlated with protein levels of XPA in testicular cancer, drawing a link between DNA 
damage repair and chemotherapeutic treatment (38).  Attempts to increase sensitivity to 
cisplatin treatment continue to be pursued as a means to increase efficacy of this 
treatment.  Currently, clinical correlations between DNA repair capacity and 
chemotherapeutic sensitivity are being investigated and the potential exists that repair 
capacity may be used as a prognostic indicator for the expected outcome following 
treatment as well as a means to individually tailor chemotherapeutic treatment.   
 Using an in silico screening assay performed by Dr. J.T. Zhang’s laboratory 
(Indiana University School of Medicine), we have identified a series of small molecules 
that dock within the DNA binding domain of XPA.  In vitro analysis of these small 
molecules by Tracy Neher (Indiana University School of Medicine) has identified a class 
of compounds that show inhibition of XPA’s DNA binding activity.  Secondary 
screening assays have confirmed one of these compounds, 3172-0796 which shows 
inhibitory activity on ssDNA, dsDNA and 1,2 Pt damaged dsDNA.  The effect of 3172-
0796 on cisplatin sensitivity on H460 cells has also been examined. 
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4.2.  Materials and Methods    
4.2.1.  Materials 
 DNA substrates were obtained from IDT (Coralville, IA) and prepared as 
described in section 2.2.3.  Sequences may be found in Appendix A.  Goat α-XPA 
primary antibody was obtained from Santa Cruz Biotechnology and goat α-rabbit 
secondary antibody was obtained from BioRad.  
4.2.2.  In silico screen of small molecule libraries 
 In silico screening experiments were performed to identify molecules predicted to 
interact with XPA’s DNA binding domain and have the potential to inhibit XPA function.  
The solution structure of XPA was obtained from the Protein Data Bank (1XPA).  
Analysis of this structure allowed for grids to be made to specifically target the DNA 
binding domain of XPA.  In silico screnning of the ChemDiv small molecule libraries 
was performed by Jianyuan Liu (Indiana University School of Medicine).  More than 
200,000 compounds were docked, screened and then scored using a DOCK GRID 
scoring function, following which the top 2000 compounds were rescored by AMBER 
score function (to determine solvation free energy) incorporated in DOCK 6. The top 
1000 compounds were then clustered and the docked compounds were visually examined 
using the UCSF Chimera ViewDock function. Approximately 100 compounds were 
determined for each library based on GRID and AMBER scores, drug likeness 
(Lipinski’s Rule of Five), and with consideration of diversifying representative 
compounds and visual examination of the docked protein-compound complexes. 
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4.2.3.  ELISA analysis of XPA binding to DNA 
 ELISAs were performed by binding 200 fmol per well of biotinylated 60-nt 
single-strand DNA in blocking buffer (2% BSA TBS-Tween) overnight on strepavadin 
coated plates (Roche Applied Science).  Ten ng of purified XPA was then incubated with 
increasing concentrations of compound as indicated for 10 minutes at room temperature 
in blocking buffer and then added to wells containing DNA for 1 hour.  Wells were then 
washed 3 x 5 minutes with blocking buffer after which primary anti-XPA antibody (Santa 
Cruz Biotechnology) (1:1000 in blocking buffer) was added for 30 minutes.  Following 
incubation with primary antibody, wells were washed 3 x 5 minutes with blocking buffer 
followed by the addition of goat anti-rabbit secondary antibody (Biorad) (1:2500 in 
blocking buffer) for 30 minutes.  Wells were then washed as described above and 100 µL 
TMB-ELISA reagent (Thermo Scientific) was added to each well.  Kinetic reads were 
performed using a SpectraMax M5 spectrophotometer for 20 minutes at 30 second 
intervals at wavelengths 490 and 370 nm.  The maximum mAbs/sec absorbance value 
was determined for each sample and represented as a percentage of the absorbance value 
obtained for the control treated sample.  The averages represent the results of duplicate 
samples from 4 independent experiments.  The IC50 and standard deviation were 
calculated by fitting the curve to a standard 2-parameter hyperbolic curve (equation 
f=(a*b)/(b+x)).  ELISA assays for the cisplatin damaged and undamaged double-strand 
substrates were performed as described above, however, 10 and 50 ng of XPA were used, 
respectively. 
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4.2.4.  Crystal violet analysis  
 H460 NSCLC cells were plated at a density of at 1 x 104 cells/cm2 and incubated 
for 24 hours at 37°C and then treated with increasing concentrations of 3172-0796 or 
vehicle in the presence or absence of 2 µM cisplatin as indicated for 48 hours.  Cells were 
also plated and treated with increasing concentrations of cisplatin with 100 µM 3172-
0796 or vehicle for 48 hours.  Following treatment, wells were washed with PBS and 
stained with crystal violet solution (0.75% Crystal Violet in 50% EtOH with 0.125% 
NaCl and 0.88% Formaldehyde) for 10 minutes.  Following staining, cells were washed 
in dH2O and the dye resolubilized with 1% SDS in PBS.  Absorbance was read at 595 nm 
using a SpectraMax M5 spectrophotometer (Molecular Devices).  
4.3.  Results 
Identification of inhibitors of XPA-DNA interactions 
 A high-throughput screen using fluorescence anisotropy as described for RPA 
was performed to identify SMIs of XPA (92).  From screening 35,200 compounds, 58 
were identified as positive hits (92).  However, none of these compounds were verified in 
FP based secondary screening assays.  We therefore chose to employ an in silico screen 
to identify potential SMIs of XPA in collaboration with Dr. J.T. Zhang’s laboratory 
(Indiana University School of Medicine).  The DNA binding domain of XPA (residues 
98-219), was divided into regions including clefts consisting of residues 138-142, 165-
171, 174 and 177-181 to be used as the targeted area for small molecule docking.  
Following the virtual screen, 63 identified compounds which may putatively inhibit 
XPA’s DNA binding activity were examined by Dr. Tracy Neher using a secondary in 
vitro FP screening assay to test the ability of each compound to interact with XPA and 
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prevent DNA binding (data not shown).  From this screen, 3 compounds were found to 
inhibit XPA’s DNA binding activity, 3172-0796, 0917-0097 and 1080-0542 (Figure 27).   
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Figure 27.  Structure of SMIs of XPA identified from fluorescence anisotropy.  27A.  
3172-0796.  27B.  1080-0542.  27C.  0917-0097. 
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In vitro analysis of SMIs of XPA 
 In order to examine the in vitro activity of the 3 lead SMIs, an ELISA based assay 
was used to assess the ability of these compounds to inhibit XPA from binding DNA.  
ELISA analysis was employed in order to reduce the spectroscopic effects observed for 
some of the small molecules and as another assay to verify in vitro inhibitory activity.  In 
order to determine the optimal concentration to measure inhibition of XPA’s DNA 
binding activity, 500 fmol of biotin conjugated 60-nt ssDNA (TMN 1.1B) was bound to 
streptavidin coated ELISA plates and the binding activity of 10 and 100 ng of XPA was 
analyzed.  Ten ng of purified XPA was found to result in ~50% of maximum XPA-DNA 
binding activity and this amount was used to examine inhibition of the XPA-DNA 
interaction.  Ten ng of XPA was pre-incubated with either vehicle or each compound for 
ten minutes and then incubated with DNA for one hour.  Following incubation, the plates 
were probed with α-XPA polyclonal antibody followed by goat α-rabbit secondary 
antibody.  TMB ELISA reagent was then added to each well and kinetic reads were 
performed to quantify the amount of XPA bound to DNA (see section 4.2.3).  Compound 
3172-0796 was shown to have the highest in vitro inhibitory activity of XPA’s DNA 
binding activity with an IC50 value of 20.9 ± 2.7 µM on ssDNA (Figure 29A).  
Compounds 0917-0097 and 1080-0542 were also examined to determine their ability to 
inhibit XPA’s DNA binding activity, however, neither of these compounds showed in 
vitro inhibitory activity when examined by this assay, when tested up to 200 µM (Figure 
28).  The ability of 3172-0796 to inhibit XPA’s DNA binding activity on undamaged 60-
nt dsDNA (TMN 1.1B/1.2) was also examined revealing an IC50 value of 38.82 ± 14.24 
µM (Figure 29B).    
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Figure 28.  ELISA analysis of SMIs of XPA.  Increasing concentrations of 0917-0097 
and 1080-0542 and 100 µM 3172-0796 were incubated with 10 ng of XPA and then 
added to strepavidin coated ELISA plates prebound with biotinylated TMN 1.1 60-nt 
DNA as described in section 4.2.3.  The amount of XPA bound to DNA was detected 
using an anti-XPA antibody and the results represent the average and standard deviation 
from at least 3 independent experiments.   
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Similarly, XPA was also found to be inhibited on a 60-nt double-strand substrate 
containing a single 1,2 cisplatin adduct (TMN 1.1B+Pt/1.2) with an IC50 value of 28.25 ± 
7.85 µM (Figure 29C).  T-test analysis of these IC50 values did not reveal a significant 
difference between them, indicating that 3172-0796 is interacting with XPA in a way that 
prevents its binding to various types of DNA substrates and also presents the possibility 
that XPA is interacting in the same way with these different substrates.  XPA has been 
shown previously to bind to damaged DNA (122), however, the mode of interaction 
between XPA and damaged DNA has yet to be determined.  Our results indicate that 
3172-0796 is preventing XPA from binding to various DNA substrates in a similar way, 
which points to an attribute of XPA that is important for binding to ssDNA, dsDNA and 
1,2 Pt damaged dsDNA.  Identification of the interaction domain between 3172-0796 and 
XPA has the potential to identify the mode in which XPA is interacting with the DNA 
substrates examined.   
Examination of XPA residues potentially important for interaction with 3172-0796 
 Examination of the structure of XPA docked with 3172-0796 reveals several 
amino acids that may contribute to the stable binding of this compound to XPA to result 
in inhibition of XPA’s DNA binding activity.  Among the amino acids examined within 
the DNA binding domain, four were identified as having putative interactions with 3172-
0796 (Figure 30).  Lysine 167 is in close proximity to the chlorine residue protruding 
from the benzoic acid and has the potential to have polar interactions with the compound 
at this position.  Threonines 140 and 142 are positioned near the pyrazole and furan ring 
of 3172-0796 with the potential for hydrogen bonding activity.    
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Figure 29.  ELISA analysis of 3172-0796 on various DNA substrates.  29A.  XPA was 
incubated with increasing concentrations of TDRL-505 as indicated and then added to 
strepavidin plates containing 500 fmol of ssDNA (TMN 1.1B).  29B.  XPA was 
incubated with increasing concentrations of TDRL-505 as indicated and then added to 
strepavidin plates containing 500 fmol of dsDNA (TMN 1.1B/1.2).  29C.  XPA was 
incubated with increasing concentrations of TDRL-505 as indicated and then added to 
strepavidin coated ELISA plates containing 500 fmol of dsDNA containing a 1,2 Pt 
lesion (TMN 1.1B+Pt/1.2).  The results display the average and standard deviation of at 
least 3 independent experiments. 
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The fourth amino acid examined which may putatively stabilize the interaction between 
the XPA DNA binding domain and 3172-0796 is histidine 171.  The potential interaction 
between this histidine and 3172-0796 is may be a hydrophobic interaction that occurs via 
ring stacking.  Identification of potential sites of interaction allows for the design of more 
specific and potent inhibitors of XPA’s DNA binding activity. 
Cellular analysis of 3172-0796 
 The exclusive role of XPA in NER predicts that single-agent cellular inhibition of 
this protein would not display signal agent activity in the absence of agents that induce 
damage repaired by NER.  However, the necessity of XPA in repairing cisplatin induced 
DNA damage indicates that its inhibition has the potential to increase cellular sensitivity 
to cisplatin.  In order to examine if 3172-0796 increases cellular sensitivity to cisplatin, 
H460 cells were treated with a fixed concentration of cisplatin and increasing 
concentrations of 3172-0796.  Following 48 hour incubation, cells were stained with 
crystal violet as described in section 4.2.4 to analyze cytotoxicity (Figure 31B).  
Interestingly, 3172-0796 did not increase cellular sensitivity to cisplatin as would be 
expected with inhibition of XPA.  Cisplatin was also titrated with a fixed concentration of 
3172-0796 which did not affect cell viability (Figure 31A).  The lack of increased 
cytotoxicity indicates that under the conditions tested, 3172-0796 does not affect cellular 
processing and/or repair of cisplatin, which may be due to an ability of the compound to 
be taken up into cells or other cellular factors. 
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Figure 30.  Modeling of 3172-0796 with XPA.  30A.  The solution structure of XPA 
was modeled with 3172-0796 as described in section 4.2.2.  The region of XPA that is 
blown up in 31B is outlined by the red square.  30B.  A close up representation of XPA 
modeled with 3172-0796.  Residues that are shown are, clockwise from far left, lysine 
167, histidine 171 and threonines 140 and 142.         
  
A 
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Figure 31.  H460 cells treated with cisplatin in the presence and absence of 3172-
0796.  31A.  Cells were treated for 48 hours with increasing concentrations of cisplatin in 
the presence or absence of 100 µM 3172-0796.  The results represent the average and 
standard deviation from at least 3 independent experiments.  31B.  Cells were treated for 
48 hours with increasing concentrations of 3172-0796 in the presence or absence of 2 µM 
cisplatin (IC30 value).   
  
A 
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4.4.  Discussion 
 Targeting proteins essential for DNA repair has been the goal of several lab 
groups in recent years.  One of the drawbacks of targeting proteins active in DNA repair 
pathways is inhibition of the repair of normally incurred DNA damage such as that 
induced by ROS.  Inhibition of these pathways has the potential to result in the 
development of secondary cancers and lead to high toxicity in non-malignant cells.  
Targeting XPA with SMIs presents an attractive approach for increasing cancer cell 
sensitivity to DNA damaging agents such as cisplatin due to the exclusive role of XPA in 
NER.  Also, NER is an essential pathway for the repair of bulky DNA damage, the 
majority of which is induced by exposure to UV-light.  Treatment of cancer patients with 
a drug targeting XPA is predicted to have few off-target cytotoxic effects when 
examining single-agent activity, a major advance and divergence from current 
chemotherapeutic treatment.  Also, unlike targeted inhibition of other pathways, there is 
no known redundancy of NER, meaning that inhibition of this pathway will prevent the 
removal the majority of cisplatin-DNA lesions.  One negative aspect to this approach is 
that global cellular sensitivity to cisplatin will increase, resulting in enhancement of the 
side-effects typically observed with cisplatin treatment including nephrotoxicity, 
ototoxicity, and gastrointestinal toxicities (123). However, the advantage of decreasing 
cancer cell growth may be worth the risk of generating these side-effects.  Another 
advantage of inhibiting XPA is the lack of redundancy of this protein, preventing other 
cellular mechanisms from compensating for its loss.  The identification of 3172-0796 
allows for the investigation and development of additional XPA inhibitors in cellular and 
mouse models and a novel target for increasing cisplatin sensitivity.  
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 Identification of residues potentially important for stabilizing the interaction of 
3172-0796 with XPA has may allow us to elucidate how 3172-0796 is interacting with 
XPA and also allow us to further understand how XPA interacts with DNA.  In addition, 
modeling of 3172-0796 within the DNA binding domain of XPA allows for the design of 
other SMIs that can inhibit XPA’s DNA binding activity, leading to a library of SMIs to 
examine for in vitro, cellular, and in vivo activity.      
5.  Conclusion 
 The global application of inhibiting the repair of cisplatin lesions, both by 
targeting XPA and RPA is appealing due to the lack of the successful development of a 
protein inhibitor that is widespread for many cancer treatments.  The interest in 
examining DNA repair both in the context of cancer development and response to 
chemotherapy has ascended to new levels, presumably because the underlying theme in 
all cancers is a change in genomic DNA that leads to mutant protein production and 
eventual uncontrolled cell proliferation.  This coupled with the lack of novel effective 
chemotherapeutics has shifted the focus of the field somewhat to “get back to basics” and 
remember that although cancers develop as a result of various protein mutations, they all 
share the common theme of deleterious mutations that result in uncontrolled cell growth 
and proliferation.  Bruce Alberts, the current editor-in-chief of Science magazine, 
recently commented on the importance of DNA repair in cancer: “…we can expect all 
cancer cells to be defective in some aspect of DNA repair that makes them unusually 
mutable.  In principle, this weakness can be exploited by finding a drug that makes the 
original defect lethal to the cancerous cell instead of just destabilizing it, without causing 
harm to normal cells. The recent discovery of the strong therapeutic benefit of so-called 
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PARP inhibitors, when used on tumors with defects in one type of DNA repair pathway, 
provides a proof of principle for organizing a major new attack on cancer.” (91).  This 
statement highlights the direction that some individuals feel the field of cancer research 
should be moving and this shift has the potential to have a vast effect on cancer 
treatment. 
 Targeted inhibition, while successful in a small percentage of cancers such as 
chronic myeloid leukemia (CML), is limiting due to wide diversity of mutations that 
result in cancer development.  CML is characterized by a chromosomal rearrangement 
that results in a constitutively active BCR-ABL kinase and successful remission of this 
cancer has been observed following treatment with imitanib, a potent and specific 
inhibitor of BCR-ABL kinase (124).  For patients suffering with CML, the development 
of imitanib provides a treatment option that will allow for remission of their cancer and 
the ability to continue with their lives.  However, for the thousands of patients that 
develop other cancers, imitanib is not an option for successful treatment.   
 The bulk of the development of novel chemotherapeutics has focused on targeted 
inhibition of proteins shown to play a role in cancer development.  However, the ability 
of cancer cells to adapt and continue to thrive despite this inhibition limits the usefulness 
of approaching cancer therapy in this manner.  Until cancer profiles have been clearly 
elucidated and physicians are able to consider inter-individual variations when choosing 
chemotherapeutic treatment, global cell killing seems to be the most effective way of 
stopping cancer growth, albeit with very undesirable side effects.  Combination therapy 
to enhance the efficacy of current chemotherapeutics such as cisplatin may prove to be an 
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essential innovation in cancer treatment that will reduce the number of mortalities 
attributable to cancer. 
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APPENDIX A.  DNA OLIGONUCLEOTIDES 
dT12 (12-mer) 
5′-TTTTTTTTTTTT-3′ 
SJC 1.5CXba (34-mer) 
5′-CTAGAAAGGGGGAAGAAAGGGAAGAGGCCAGAGA-3′ 
SCS 1.1 (40-mer) 
5′-TCATTACTACTCACTCTGTCGG
SCS 1.2 (41-mer) 
CCATCGCTCTCTATTCCC-3′ 
5′-GGGGAATAGAGAGCGATGGCCGACAGAGTGAGTAGTAATGA-3′ 
TMN 1.1B (60-mer) 
5′-/5Biotin/CCCTTCTTTCTCTTCCCCCTCTCCTTCTTGG
CCTTCCCTTTCCTCCCC-3′ 
CCTCTTCCTTCC 
TMN 1.2 (60-mer) 
5′-GGGGAGGAAAGGGAAGGGGAAGGAAGAGGCCAAGAAGGAGAGGG 
GGAAGAGAAAGAAGG-3′ 
*Underlined bases indicate sites to induce cisplatin damage. 
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